Investor Partnerships

A directory of selected investor partnerships
<table>
<thead>
<tr>
<th>24 Haymarket Limited</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACT Venture Partners</td>
<td>5</td>
</tr>
<tr>
<td>Ada Ventures</td>
<td>6</td>
</tr>
<tr>
<td>Albion Capital Group LLP</td>
<td>7</td>
</tr>
<tr>
<td>Amadeus Capital Partners</td>
<td>8</td>
</tr>
<tr>
<td>Angel Academe</td>
<td>9</td>
</tr>
<tr>
<td>Angels@Essex</td>
<td>10</td>
</tr>
<tr>
<td>Anglo American Decarbonisation Ventures</td>
<td>11</td>
</tr>
<tr>
<td>Anticus Partners</td>
<td>12</td>
</tr>
<tr>
<td>Archangels</td>
<td>13</td>
</tr>
<tr>
<td>Ascension Ventures Limited</td>
<td>14</td>
</tr>
<tr>
<td>Astanor</td>
<td>15</td>
</tr>
<tr>
<td>Baltic Ventures</td>
<td>16</td>
</tr>
<tr>
<td>Barclays Sustainable Impact Capital</td>
<td>17</td>
</tr>
<tr>
<td>Beringea</td>
<td>18</td>
</tr>
<tr>
<td>Black Seed Ventures</td>
<td>19</td>
</tr>
<tr>
<td>Bloc Ventures</td>
<td>20</td>
</tr>
<tr>
<td>Boundary Capital Partners</td>
<td>21</td>
</tr>
<tr>
<td>Cambridge Angels</td>
<td>22</td>
</tr>
<tr>
<td>Cambridge Enterprise</td>
<td>23</td>
</tr>
<tr>
<td>Cancer Research Horizons</td>
<td>24</td>
</tr>
<tr>
<td>Carbon13</td>
<td>25</td>
</tr>
<tr>
<td>Catapult Venture Managers Limited</td>
<td>26</td>
</tr>
<tr>
<td>Chrysalix Venture Capital</td>
<td>27</td>
</tr>
<tr>
<td>Cibus Capital</td>
<td>28</td>
</tr>
<tr>
<td>Clarendon Fund Managers Limited</td>
<td>29</td>
</tr>
<tr>
<td>Clean Growth Fund</td>
<td>30</td>
</tr>
<tr>
<td>Concept Ventures</td>
<td>31</td>
</tr>
<tr>
<td>Cornerstone VC</td>
<td>32</td>
</tr>
<tr>
<td>Cottagequinn Enterprises Ltd</td>
<td>33</td>
</tr>
<tr>
<td>Counteract</td>
<td>34</td>
</tr>
<tr>
<td>CPT Capital LLP</td>
<td>35</td>
</tr>
<tr>
<td>Creative UK</td>
<td>36</td>
</tr>
<tr>
<td>Creator Fund</td>
<td>37</td>
</tr>
<tr>
<td>Deepbridge Capital</td>
<td>38</td>
</tr>
<tr>
<td>Deep Science Ventures</td>
<td>39</td>
</tr>
<tr>
<td>Deeptech Seed Fund</td>
<td>40</td>
</tr>
<tr>
<td>Development Bank of Wales</td>
<td>41</td>
</tr>
<tr>
<td>DSW Venture Capital LLP</td>
<td>42</td>
</tr>
<tr>
<td>Earlymarket LLP</td>
<td>43</td>
</tr>
<tr>
<td>Earth Capital</td>
<td>44</td>
</tr>
<tr>
<td>East Innovate Ltd</td>
<td>45</td>
</tr>
<tr>
<td>Ebico</td>
<td>46</td>
</tr>
<tr>
<td>EKA Ventures</td>
<td>47</td>
</tr>
<tr>
<td>Elbow Beach Capital</td>
<td>48</td>
</tr>
<tr>
<td>Elsoms Seeds</td>
<td>49</td>
</tr>
<tr>
<td>Eos Advisory</td>
<td>50</td>
</tr>
<tr>
<td>Epidarex Capital</td>
<td>51</td>
</tr>
<tr>
<td>Equity Gap</td>
<td>52</td>
</tr>
<tr>
<td>Extantia</td>
<td>53</td>
</tr>
<tr>
<td>Fearless Adventures</td>
<td>54</td>
</tr>
<tr>
<td>Foresight WAE Technology Fund</td>
<td>55</td>
</tr>
<tr>
<td>FOV Ventures</td>
<td>56</td>
</tr>
<tr>
<td>Future Planet Capital</td>
<td>57</td>
</tr>
<tr>
<td>Name</td>
<td>Page</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>GC Angels</td>
<td>58</td>
</tr>
<tr>
<td>Green Angel Ventures</td>
<td>59</td>
</tr>
<tr>
<td>Henley Business Angels</td>
<td>60</td>
</tr>
<tr>
<td>HERmesa</td>
<td>61</td>
</tr>
<tr>
<td>HG Ventures</td>
<td>62</td>
</tr>
<tr>
<td>Hiro Capital</td>
<td>63</td>
</tr>
<tr>
<td>IP Group plc</td>
<td>64</td>
</tr>
<tr>
<td>IQ Capital Partners LLP</td>
<td>65</td>
</tr>
<tr>
<td>Jenson Funding Partners LLP</td>
<td>66</td>
</tr>
<tr>
<td>Kelvin Capital Limited</td>
<td>67</td>
</tr>
<tr>
<td>KHP Ventures</td>
<td>68</td>
</tr>
<tr>
<td>Kindred Capital</td>
<td>69</td>
</tr>
<tr>
<td>LCR Ventures Limited (LYVA Labs)</td>
<td>70</td>
</tr>
<tr>
<td>London Venture Partners</td>
<td>71</td>
</tr>
<tr>
<td>Longwall Venture Partners LLP</td>
<td>72</td>
</tr>
<tr>
<td>Low Carbon Innovation Fund</td>
<td>73</td>
</tr>
<tr>
<td>Maven</td>
<td>74</td>
</tr>
<tr>
<td>Mercia Ventures</td>
<td>75</td>
</tr>
<tr>
<td>Minerva Business Angels</td>
<td>76</td>
</tr>
<tr>
<td>MMC Ventures Limited</td>
<td>77</td>
</tr>
<tr>
<td>M Ventures</td>
<td>78</td>
</tr>
<tr>
<td>Nesta</td>
<td>79</td>
</tr>
<tr>
<td>NoBa Capital</td>
<td>80</td>
</tr>
<tr>
<td>Northern Angel Hub</td>
<td>81</td>
</tr>
<tr>
<td>Northern Gritstone Limited</td>
<td>82</td>
</tr>
<tr>
<td>Northstar Ventures Limited</td>
<td>83</td>
</tr>
<tr>
<td>o2h Ventures</td>
<td>84</td>
</tr>
<tr>
<td>Octopus Ventures Limited</td>
<td>85</td>
</tr>
<tr>
<td>Old College Capital</td>
<td>86</td>
</tr>
<tr>
<td>OnePlanetCapital</td>
<td>87</td>
</tr>
<tr>
<td>Oxford Science Enterprises Plc</td>
<td>88</td>
</tr>
<tr>
<td>Oxford Technology</td>
<td>89</td>
</tr>
<tr>
<td>Par Equity LLP</td>
<td>90</td>
</tr>
<tr>
<td>PDS Ventures</td>
<td>91</td>
</tr>
<tr>
<td>Pioneering Ventures Limited</td>
<td>92</td>
</tr>
<tr>
<td>Praesidium S.A.</td>
<td>93</td>
</tr>
<tr>
<td>Praetura Ventures Limited</td>
<td>94</td>
</tr>
<tr>
<td>Prostate Cancer Research</td>
<td>95</td>
</tr>
<tr>
<td>Qantx</td>
<td>96</td>
</tr>
<tr>
<td>Qubis</td>
<td>97</td>
</tr>
<tr>
<td>Rabo Investments</td>
<td>98</td>
</tr>
<tr>
<td>Regenerate Ventures</td>
<td>99</td>
</tr>
<tr>
<td>Sainsbury’s Innovation Investments</td>
<td>100</td>
</tr>
<tr>
<td>SCVC</td>
<td>101</td>
</tr>
<tr>
<td>SETsquared</td>
<td>102</td>
</tr>
<tr>
<td>SFC Capital Ltd</td>
<td>103</td>
</tr>
<tr>
<td>Social Tech Trust</td>
<td>104</td>
</tr>
<tr>
<td>SOSV</td>
<td>105</td>
</tr>
<tr>
<td>Speedinvest</td>
<td>106</td>
</tr>
<tr>
<td>Start Codon</td>
<td>107</td>
</tr>
<tr>
<td>Sure Valley Ventures</td>
<td>108</td>
</tr>
<tr>
<td>Sustainable Venture Development Partners</td>
<td>109</td>
</tr>
<tr>
<td>Techstart Ventures</td>
<td>110</td>
</tr>
<tr>
<td>Tern PLC</td>
<td>111</td>
</tr>
<tr>
<td>The Conduit Connect</td>
<td>112</td>
</tr>
<tr>
<td>The Yield Lab</td>
<td>113</td>
</tr>
<tr>
<td>TSP Ventures</td>
<td>114</td>
</tr>
<tr>
<td>Twin Path Ventures</td>
<td>115</td>
</tr>
<tr>
<td>Two Magnolias</td>
<td>116</td>
</tr>
<tr>
<td>VisViRes New Protein</td>
<td>117</td>
</tr>
<tr>
<td>Zinc Ventures</td>
<td>118</td>
</tr>
</tbody>
</table>
24Haymarket invests aligned private capital to accelerate the commercial success of businesses at the early stages of commercial adoption. Investing up to £5 million in a round (with a target initial investment of £2–3 million) and up to £10 million in any single company over a number of rounds.

We operate a hybrid funding model with over 100+ high profile operator, entrepreneur and investor angel investors who have collectively invested over £100 million in our portfolio. This is complemented by two committed capital vehicles to better support the capital demands of our portfolio as it successfully scales. To-date we have backed over 60 high-growth businesses.

We focus our efforts on a few key areas with strong growth tailwinds including cybersecurity, climate tech, supply chain and logistics, IoT/robotic automation and digital healthcare. We actively provide post-investment support via board involvement through our angel syndicate with the addition of strategic and tactical commercial support (in particular the facilitation of commercial introductions). We have an excellent track record of both enabling later-stage follow-on investment and trade and private equity exits.
ACT Venture Partners (ACT) is an experienced early-stage VC investor with a proven track record of backing deep tech ventures in Europe and the UK. The fund manager and the funds under management are regulated in the Netherlands under the EU AIF and AIFM. We have a dedicated investment team here in the UK.

We define the deep tech sector as one that includes spin-offs and startups whose business is built around unique, differentiated, often protected or hard-to-reproduce technological or scientific advances. Our primary focus is the following technology areas: (1) Emerging Digital Technologies, (2) Technologies for Healthcare, and (3) Technologies Serving Sustainability.

We invest predominantly starting from the Seed stage and continuing in the following rounds. We prefer an ownership target of 10-20% per deal by investing EUR 500k - EUR 1 Mn as an initial investment.

We also like to lead or co-lead the investment rounds. We can allocate up to EUR 5 Mn per deal for follow-on rounds.

Our three pillars of the selection criteria are - the team, problem-solution fit, and product-market fit.

Early-stage deep tech ventures have to cope with numerous challenges. We help them on these from day one: (a) growth strategy, (b) Series A readiness, (c) Catalysing Networking, and (d) corporate governance.

For applications: info@actvp.vc
Ada Ventures is the inclusive venture firm. Ada Ventures finds and funds extraordinary talent building breakthrough ideas for the hardest problems we face. We are investing out of our second fund, and we invest £250,000 - £2m in UK technology companies across climate, economic empowerment and healthcare & ageing.

If you are a UK tech company with a mission to develop proprietary technology and are raising pre Series A stage capital, we’d love to hear from you.

Investment from Ada Ventures comes with a funding partner that can support or lead 1-3 seed rounds ahead of Series A. We are also your partner in building a diverse organisation with social impact agendas.

Ada Ventures
adaventures.com

Find out more:
medium.com/ada-ventures

Submit Your Deck:
adaventures.typeform.com/adasubmissions
AlbionVC supports visionary founders with long-term capital and scale-up expertise. It partners with UK early-stage B2B software, deeptech and healthcare companies. AlbionVC manages c. $1 billion of venture funds, currently invested in over 60 companies.

Our VCTs invest from Seed to Series B in software and healthcare businesses. UCL Technology Fund invests from Pre-Seed to Series A in businesses founded on world-class research in life sciences, physical sciences and computer sciences from University College London.

We are supportive investors, not operators, who strive for excellence and show ethics and humility in our interactions with founders and each other. We invest in startups with potential to grow into enduring companies that reshape industries. In doing so we achieve top quartile returns for our investors.

Our experience of investing over the last 26 years has given us the ability to spot companies that are set to become global category leaders and has shaped our understanding of the tools and support we can offer them on the journey.

All of this is only possible because of the long term, considerate yet high performing culture, embodied by an inspiring team, half of whom have been doing this for well over a decade.
Amadeus Capital Partners

Amadeus was founded in 1997 by Anne Glover (formerly at APAX Partners and Bain & Co) and Hermann Hauser (co-founder of Acorn Computers which spun out ARM, the microprocessor giant). In the subsequent 25 years, Amadeus has invested more than $1 billion across 22 funds and remains a trailblazer in European venture capital.

Anne and Hermann are active in the firm and serve on the Investment Committee of the funds. The firm has backed more than 190 companies and returned funds to its underlying LPs through 90 exits including 17 IPOs. Amadeus invests in deep tech and tech-enabled companies that have the potential to become global champions. Amadeus has three strategies namely, Early Stage, Growth European and Growth LatAm and operates from London, Cambridge and Oxford in the UK, San Francisco and São Paulo.

The team focusing predominantly on the UK market comprises four experienced Partners: Amelia Armour, Dr Manjari Chandran-Ramesh, Nick Kingsbury and Pierre Socha. This team benefits from in-depth sector experience in deep tech venture investing and covers sectors like Artificial Intelligence (AI), Cybersecurity, Photonics, Quantum, Digital Health, Medical Technology, Novel Materials, Environmental and Climate Tech. They have raised more than £210 million and deployed over £100 million since 2013 into early-stage deep tech companies.

The company prides itself on its diversity internally, across the portfolio and across the broader network. Amadeus has over 50% gender diversity and people from nine nationalities speaking 12 languages. As well as diverse characteristics, education and work experience, the team offers diversity of thought with backgrounds in entrepreneurship, investment banking, accounting and deep scientific knowledge.

The investment approach is to pick companies that have a disruptive and deep technical differentiation coupled with a star team addressing a huge and growing market.
Angel Academe is a leading UK angel network that has backed 48+ businesses since 2014, helping them raise over £150m from angels, VCs and family offices to continue to grow their businesses. We invest in early-stage, ambitious and highly scalable technology startups with at least 1 woman on the founding team.

As a network, we have an appetite for calculated risk & potentially higher returns than other asset classes. 70% of us are women, but men who want to be part of a diverse network are also very welcome. We have structured processes for thorough due diligence and supporting the businesses post-investment.

Angel Academe portfolio companies not only benefit from access to smart, engaged, diverse capital, but also timely introductions, industry-specific expertise and a growing community of founders and funders.

Investment criteria:

- You’re a female founder or co-founder who owns at least 20% of founder equity in the business (pre-dilution). You will run the fundraising activity with our investors
- Your technology startup has an innovative solution to an important global problem in areas including fin tech, med tech (digital and devices), ed tech, cyber security, clean tech and enterprise
- You have relevant industry, technical and startup experience in your team and a strong vision for the future of your business
- You have a working product, business model and market traction
- B2B businesses are preferred but we will consider B2C opportunities with significant and growing revenue, ideally recurring
- You can articulate clear differentiation from your competition and good barriers to entry for potential new entrants
- You’re addressing a large global market and can show how you will return a minimum 10X to investors within 3-10 years
- You’re a UK business with a £1m - £15m pre-money valuation and eligible for SEIS and/or EIS tax relief
- You’re raising £250,000-£5,000,000 of equity investment in a priced round
- You’re able and willing to work with external advisors and recognise the value of a diverse cap table.

We run weekly screening & selection calls with our screening committee, and monthly pitch events for our investor network. The best way to apply to pitch the network is through the link below - no warm intro needed!

www.angelacademe.com/apply-to-pitch
Angels@Essex is an invitation-only investment platform that links angel investors to entrepreneurs with innovative ideas, allowing new disruptive technologies to flourish.

The Angels@Essex platform allows entrepreneurs to display their pitch decks to a select number of invited investors.

We take no incentives, no commissions, and no fees. It's secure and easy to use - once you have gone through our investment readiness full eligibility appraisal and due diligence process, you can get started right away.

Our focus is on innovative and market disruptive technologies, probably B2B, research intensive with MVP. If you are not sure if you are eligible, why not just ask us first, we would be pleased to explore any potential ideas with you.

Angels@Essex
bit.ly/angelsessex

Contact:
uez@essex.ac.uk

Our University of Essex is noted for its research into deep tech across many sectors that include Health Tech, FinTech, AgriTech, AI, VR, AR, Data Science, but not exclusively. Why not tap into this wide resource availability.
Anglo American’s Decarbonisation Ventures team invests in start-ups with the potential to achieve greater than 0.5Gt of decarbonisation per year of scale.

With over a decade of corporate venturing experience, we are committed to making a positive impact beyond our operations, in order to unlock the potential of technological innovation and cross-industry collaboration.

Type of companies we invest in - Early-stage start-ups, between pre-seed round and Series A investment rounds. We prioritise investments in the following focus areas: sustainable materials (including the steel value chain); clean energy (beyond wind and solar; and including storage solutions); carbon and nature; and methane and agriculture.
We are equity investors currently with two funds under management, The Finance Yorkshire Seedcorn Fund and The Finance Yorkshire Growth Fund. The Finance Yorkshire Seedcorn Fund invests in early stage startup companies which are located in the Yorkshire and the Humber region. This Fund is sector-agnostic and can invest up to £1.5m in businesses which are looking to scale and grow from the commercialisation of existing intellectual property. The Finance Yorkshire Growth Fund invests in profitable companies which are located in the Yorkshire and the Humber region. We aim to support businesses as they transition to their next phase of growth and ownership and seek to invest up to £1.5m into a variety of transactions including MBOs, replacement capital and development capital.

We seek to empower Yorkshire’s talented and ambitious entrepreneurs to climb new global heights for a brighter future. Our team has deep-rooted connections to the region, with extensive knowledge of the local business community. Anticus Partners seeks to make a difference to the people and environment in which we operate.
Archangels is a prominent business angel syndicate, which has been at the forefront of early stage investing in Scotland for over 30 years. We provide our members with carefully-curated opportunities to invest in the most innovative companies and to support their early stage development to fullest potential.

We typically invest as lead investor in businesses which are located and registered in Scotland. Archangels welcomes funding submissions from start-ups and early stage companies in the technology and life sciences sectors.

Our Criteria is:
1. MUST be both operationally based and registered in Scotland, UK.
2. The investment opportunity can cover a range from ‘proof of concept’ through expansion capital, including start-up, early stage or series A but must have high growth potential, including international sales potential.
3. Should have Intellectual Property (IP): defendable, disruptive technology and / or know-how, difficult to replicate.
4. Must be in a sector which qualifies under the Enterprise Investment Scheme.
5. Must be a technology or life science business with a B2B business model.
6. Seeking initial funding of £250k to £2m.

Archangels offers the benefit of occupying an area of the funding market which straddles traditional business angel funding and moves into the area occupied traditionally by venture capital. Portfolio companies receive the benefit of having access to the wide Archangels network including our members and the other portfolio companies. The business angel approach allows for greater alignment with our portfolio companies. Archangels also takes a patient capital approach, understanding that building a successful technology business from scratch takes time.

Archangels
archangelsonline.com

Contact:
investment@archangelsonline.com
Ascension is an early-stage venture capital firm built and managed by exited operators and entrepreneurs to back the next generation of tech and impact founders. Since 2015, Ascension has invested in 150+ start-ups across its (S)EIS & Institutional funds – our specialist approach and extensive sector reach allow us to identify and scale pioneering tech enterprises.

With over £83m under management, Ascension was crowned Seed VC of the Year in 2022 by the UK Business Angels Association and is the most active investor in the UK in the past decade (Beauhurst). Ascension has a particular focus on backing impact businesses leveraging the power of technology to solve some of the world’s biggest problems. For more information, see ascension.vc.

- The core Ascension team (now 15 individuals) and shareholders are exited tech entrepreneurs and successful investors in their own right
- 12 recent exits and approx 70+ Ascension investments valued at approx 200%
- 4 Ascension maturing funds have passed, or closed in on, 300% value: SEIS ‘15, SEIS ‘16, EIS ‘17, SEIS ‘19
- Hosted in the offices of O2 Telefonica’s global accelerator, Wayra
- Team has spent majority of their careers investing in and managing technology businesses
- Ascension VPs (17 shareholders + 2 shareholder directors) each own a stake in the business and have multiple $100m+ and $1bn+ exits from their own businesses and angel investments
- 30+ Mentors bring their expertise in building businesses, ranging from start-ups to global companies operating in the Funds’ sectors.

Ascension has adopted an investment approach that focuses on three key elements of any potential business: the quality of the team, the robustness of the technology vs. competition and market size/potential of the product. Analysis is then conducted to discern whether there is a clear route to market for the distribution of the product and to decide where Ascension can add value.

Why we add value:
- We have been investing since 2015 - investing in over 150+ companies, 12 exits, 70+ businesses trading at approx 2x and only a few failures - so have built strong co-invest / follow on relationships with key angels / funds across the UK
- We have a diverse team / venture partner network / mentors all with the sole focus to help investee companies scale
- We have sector specific funds with more focus, e.g. the Life Fund which has an extensive advisor network which is both scientific and commercial and the Conduit.

Ascension Ventures Ltd
ascension.vc/

Contact: toyosi@ascension.vc
Astanor Ventures is a global B Corp certified impact venture capital investor that backs ambitious entrepreneurs with disruptive, scalable solutions that will create systemic change across the agrifood value chain, from soil to gut.

With a demonstrated commitment to sustainability and impactful investments, Astanor Ventures identifies and nurtures early-stage companies that harness technology to drive positive change. With a keen focus on climate transition, nature positivity, resource efficiency, and social and health enhancements, Astanor Ventures is at the forefront of fostering a regenerative and sustainable bioeconomy.

Astanor’s team of experts do not only provide management and business advises, they support the portfolio companies all along their sustainable journey and help them measuring their impact creation.

Contact: entrepreneurs@astanor.com
Baltic Ventures is a tech accelerator on a mission to support game-changing founding teams who are building the solutions and businesses of tomorrow. From our hyper-local base in Liverpool’s Baltic Triangle we accelerate early-stage digital tech businesses with global ambition.

Baltic Ventures Accelerator is for founding teams with a digital MVP and early traction and offers a 4-month cohort programme, including £50k of equity investment from our angel syndicate, in-person weekly workshops, VC investor meetings, and mentorship.

Baltic Ventures Accelerator 2023 is for you if:
• You are a digital tech business with an MVP and are considering raising seed investment over the next 6-12 months and want to significantly raise your profile with investors
• You want to upskill as a founder and avoid the common startup pitfalls, on an intensive market leading programme lead by a top tier team who have been there and done it
• You want to refine your product and to further your product market fit, understand your customers better, and prepare for scalable growth

Our Accelerator programmes open for investment applications annually each Spring. Please note that we do not currently invest outside of our Accelerator Programme.
The Barclays Sustainable Impact Capital investment mandate is to invest £500 million in the equity of fast-growing, technology start-ups by 2027, helping to accelerate our clients’ transition towards a low-carbon economy.

The mandate is seeking out and supporting clear, scalable propositions that deliver both environmental benefits and economic returns as well as aligning with Barclays values and target the goals and timelines of the Paris Agreement. Through the mandate, we aim to fill growth stage funding gaps to help accelerate and scale catalytic and strategic solutions to environmental challenges.

We have a range of investments across a number of themes, including energy security, transport, biodiversity, retrofitting, circular economy, etc. Details can be found on our website. We hope to connect these companies to the wider Barclays network, creating value for them but also our customers and clients.
Beringea is a transatlantic venture capital investor that seeks to create lasting success for rapidly scaling entrepreneurial companies. We provide patient and intelligent capital and a global footprint to back entrepreneurs throughout their journey.

We’ll typically make an initial investment between £1-10 million into companies turning over approximately £1 million or more. We tend to lead Series A or Series B rounds, with further funding available for follow-on investments.

We typically look for:

- Experienced entrepreneurs - Serial founders, industry leaders, or academic experts with a clear vision for the company’s future
- Solid foundations - Proven commercial traction with a defensible market position and capital use plan to fuel growth
- Growth potential - A growing business with a substantial addressable market, a compelling product or service, and a competitive edge
- Capital efficiency - A focus on financial and operational metrics with a clear route to profitability following our investment.

How we add value:

- Beringea Scale-Up Academy - Our series of virtual and in-person events offer the leadership teams of our global portfolio of companies networking opportunities and training to overcome barriers to scale
- Supporting transatlantic growth - We use our network of advisers, provide on-the-ground support and share knowledge across our portfolio to help companies expand across the Atlantic
- Building leadership teams - We know talent drives success, so we work closely with founders and a robust network of recruitment specialists to build exceptional teams
- Providing strategic connections - From entrepreneur advisory panels to prospective client introductions, our portfolio companies can leverage our professional network to expand their reach and gain from new perspectives.

Beringea
beringea.co.uk

Contact:
info@beringea.co.uk
Black Seed is a community led by Black founders, for Black founders. Rooted in Brixton, with global ambition. We invest in pre-seed companies aimed exclusively at Black founders across the UK that will shape the Future Economy. Our core focus areas are:

- Fintech - financial services, insurtech, blockchain
- Smart Enterprise - software, automation, mobility
- Mobility & Transportation - net zero, electrification and autonomous software
- Marketplace - e-commerce and media
- DeepTech - space, open security, robotics, compute platforms, AI
- Healthcare - next-generation therapeutics, computational genomics, healthcare IT / infrastructure, digital health.

We support companies from seed, with the aim of setting up Black-led businesses for long-term success, providing our portfolio companies a six month fully bespoke operating programme that includes operational support in: tech and data science, product and UX/UI design, growth, brand, PR & comms, talent etc alongside mentoring.

Our venture studio will provide a 6 month bespoke wrap around component for our cohort providing access to our "Friends of Black Seed" network, online courses, free events & seminars and daily support and access to the Black Seed team.

Black Seed Ventures
blackseed.ventures

Contact:
info@blackseed.ventures
Bloc Ventures is an early-stage venture capital investment company, focused on deep tech companies in the UK and Europe. We invest in companies tackling complex, science-based challenges, between Seed and Series A. Our team is made up of engineers and former enterprise leaders from Arm and Vodafone, who have built global deep tech companies, collectively have made £500m+ of deep tech investments and achieved £5bn+ of exits.

Bloc’s background informs our investment focus and so typically, we focus on telecommunications and computing. We categorise their offerings across cloud, connectivity, data science and security. We produce in-house research on the future, culminating in a ‘live’ roadmap to mass adoption of particular technologies and determining where we should invest capital. Bloc’s portfolio is a mix of companies pushing the boundaries in areas such as AI, channel coding, quantum security and supercomputing.

While at Arm and Vodafone, our leadership team built relationships with the most innovative companies in the world through both commercial and financial transactions. The two co-founders led the respective venture capital units at those two firms, with deep experience prior to that in the industry. This allowed us to build a benevolent environment for our portfolio to engage with in both the telecoms and computing industries across the world. We have real world enterprise and startup experience, which we use to support entrepreneurs on anything from hiring, go to market strategy and global expansion.

Bloc’s approach has been developed over decades in engineering, investment, and M&A. This gives us unrivalled insight into technology and a unique approach to managing investments. To date, Bloc has made 13 investments and achieved 2 market-leading exits.
Boundary Capital Partners LLP is an impact, for-profit, B2B technology investor. We are regulated by the FCA as a venture capital investor. Typically we invest early stage to Series A up to £500k per investment round (we can follow our money).

We have invested in life sciences, medical devices, materials, engineering and software all within our Impact Life Fund where we have a proprietary impact methodology (“Equivalent Lives Impacted” or “ELI”) that transcends any technology type to validate the positive impact on humanity. This aligns very strongly with Innovate UK’s Plan for Action.

We have also launched the Boundary Net Zero Technology Fund which sets out to invest in disruptive technologies addressing decarbonisation, directly or indirectly. We have invested and co-invested with Innovate UK several times as a fund and within our investee companies.

We are made up of experienced entrepreneurs and investors, and we have a wealth of expertise and connectivity to bring as required in terms of business development, product development, technology R&D and strategy to finding partners and exiting.

We are always happy to speak to businesses at any stage in their investment cycle, try to help and align towards investment where there’s a fit.
Cambridge Angels is a leading UK business angel network providing smart capital from entrepreneurs to entrepreneurs. Members invest in and mentor high quality start-up and early-stage companies in Cambridge, London, Oxford and throughout the UK.

We are a collaborative Cambridge-based group, actively mentoring and investing in innovative teams and their ideas. We equip generations of entrepreneurs to generate returns and help realise their full potential. We have a strong ethos of backing merit and supporting entrepreneurship.

Our members, most of whom are successful entrepreneurs, invest in a wide range of start-up and scale-up businesses with a particular focus on deep-tech, and tools and technologies supporting healthcare. Typical funding requirements that Cambridge Angels meet are in the range of £150k to £1.5m - although it is worth noting that several of our portfolio companies have raised significant follow-on funding from our members and our venture capital partners over several funding rounds.

Our members have been responsible for a large number of the “Cambridge Phenomenon” success stories over recent years. Therefore, in addition to providing funding for early-stage companies, Cambridge Angels also offer start-ups the considerable benefit of a wide range of expertise, contacts and directly relevant experience in establishing and growing entrepreneurial businesses successfully.

Through our members and their networks, our entrepreneurs are better connected.

Cambridge Angels
cambridgeangels.com

Contact:
info@cambridgeangels.net
Cambridge Enterprise Seed Funds has managed investments made by the University of Cambridge Venture Fund into new technology companies since 1995. Investing ringfenced capital from the University of Cambridge balance sheet, the fund is an evergreen impact investor.

Cambridge Enterprise Seed Funds, the fund manager, has considerable experience in growing and establishing successful business. Over 150 companies have been invested in across a wide range of sectors to date.

Investments connect strongly to the University of Cambridge through either:

- A deep technology or research connection to the University of Cambridge
- A founding team including staff, students or recent alumni of the University of Cambridge.

The University of Cambridge invests in breakthrough technology companies from across the sciences by providing £50-500K investment as part of a syndicated round at pre-seed, seed and series A.

Contact:
innovateuk@enterprise.cam.ac.uk
Cancer Research Horizons (CRH, trading name for Cancer Research Technology Limited) is a specialist drug discovery, development and commercialisation company wholly owned by Cancer Research UK (CRUK, the world’s leading cancer charity) that fast tracks scientific breakthroughs for patient benefit.

Our CRH Seed Fund (launched June 2022) builds on over 25 years of CRH establishing and growing successful companies (approx 60 companies formed and 21 exits to date). Our fund brings innovative cancer ideas together with early stage capital, commercial advice, support with intellectual property, access to experts, mentors and management teams, and introductions to co-investors to maximise the chances of start-ups becoming financially attractive to investors and benefiting cancer patients. We specialise in high tech ideas.

Our aim is to grow the CRH Seed Fund to £30m, and it is currently backed by a commitment of £15.5m from CRUK.

Our CRH Seed Fund Investment Strategy:

Our CRH Seed Fund is an impact-driven, evergreen, venture philanthropy fund investing in promising early-stage opportunities worldwide. We take a long-term view, so we can take risks where others cannot. We can invest alone or alongside other like-minded investors.

Any financial returns we generate are reinvested back into the fund and into cancer research. Investment decisions are made based on the potential to reach a value inflection point that will leverage and attract high quality follow-on capital that will increase the chances of life-saving cancer treatments, diagnostics and devices reaching the market.

You do not need to be (or have been) a CRUK-funded researcher to secure capital from our fund. We are interested in all ideas that could benefit new cancer patients and fulfil our investment criteria, including new therapeutics, preventative measures, diagnostics, medical devices and AI/data driven solutions.

Funding available is:

- Early-stage validation capital and Pre-Seed capital: up to £150k
- Seed capital: typically £100-500k, with the ability to invest up to £1m on occasion
- Follow-on capital for our seed invested portfolio companies: typically £100-500k, with the ability to invest up to £1m on occasion.

Our seed fund, venture build and portfolio investments benefit from the support of our dedicated seed fund team and wider commercial partnerships team with long-standing track record of sourcing, evaluating and completing spinout and partnering deals. Our seed fund team works alongside an independent investment committee comprising a diverse group of investors, venture builders and experts in science, knowledge transfer and industry.

Contact:
tanya.moore@cancer.org.uk
Carbon13 selects, supports and invests in determined people through our venture building programmes, focused specifically on building scalable climate ventures that will reduce and remove emissions on a global scale. This means to be eligible for investment, startups must go through either our venture builder or venture launchpad. Information on both programmes, investment terms and start dates for the next cohort are on the Carbon13 website.

The climate crisis needs determined founders committed to this challenge, including scientists, engineers, and serial entrepreneurs. Every startup we invest in must have the potential to reduce or remove CO₂e emissions by net 10 million tonnes per year when at scale. This is a key requirement. Our community is rooted in our mission to fight the climate emergency, and driven by our scalability ethos. This is where climate tech startups will succeed on a global scale.

Our Cambridge origins have taught us the importance of commercial, carbon and scientific understanding. Our growth to Berlin fuels our ecosystem of domain expertise, investors, and partners.
Catapult Ventures is an independent venture capital fund manager, investing in UK businesses since 2002. We have managed a number of discrete venture capital funds on behalf of a range of public and private sector investors, including the GM & Cheshire Life Sciences Fund, which has invested in over forty life science businesses since launch.

Catapult Ventures is not currently investing in new companies, but we continue to invest in our portfolio companies and help to build value and growth. Catapult Ventures is all about value creation through long term relationships - both with our portfolio companies and those who have invested in the funds we manage. We have a passion for business and enjoy supporting ambitious entrepreneurs and management teams who share this enthusiasm.

Catapult Ventures is a trading name of Catapult Ultimate Holdings Ltd, which is the ultimate holding company of Catapult Venture Managers Ltd, which is authorised and regulated by the Financial Conduct Authority (FCA Registration No. 191949).
Chrysalix is a global venture capital firm that specialises in transformational industrial innovation. Our new fund, the Chrysalix Carbon Neutrality Fund, supports carbon neutral targets of hard to abate industries and invests in solutions like alternative fuels, materials substitution, carbon as a resource, carbon removal, utilisation and carbon markets make initial investments primarily at the early stage (pre-seed to Series A) and typically lead financings.

With a very active approach to supporting entrepreneurs to better outcomes, Chrysalix has deep experience building startups in cleantech and climate since 2001 and recently also emphasized digital intelligent solutions for industrial applications.

Our strategy is to build a strong ecosystem around us including blue chip industrials. Our past and current strategic investors include Shell, Total, EDF, BASF, Mitsubishi, Hitachi, Hyundai, Caterpillar, Petronas, Teck Resources and South32.

With offices on both sides of the Atlantic, we are well-connected to leading North American and European climate investors (both financials and CVCs) to create syndicates for follow on financings.
Cibus Capital LLP advises the Cibus funds which are global food and agriculture private equity and venture capital funds.

Set up in 2016, Cibus Capital has over USD 1bn under advisement to date, deployed across a portfolio of investments operating throughout the food supply chain in both mid-market and venture capital. We partner with companies driving sustainability and resource efficiency across the food value chain and help to grow companies leading the sustainable food revolution.
Clarendon Fund Managers manage Co–Fund NI, a £50m fund making equity investments in the Northern Ireland region. Co–Fund NI co–invests alongside private investors such as venture capital firms, business angels and corporate investors into high–growth potential opportunities.

Typical investment sectors include life sciences, medtech, enterprise software and net–zero & sustainable technologies. Co–Fund NI can make investments between £100,000 to £500,000 as part of investment rounds between £250,000 up to £3m.

Each investee company has access to a Clarendon investment professional who can guide management on the venture growth journey. Clarendon’s partnerships with cloud hosting providers reduce costs and maximise technology capability across its portfolio. Clarendon is also able to leverage its extensive network of entrepreneurs and investors to locate experienced advisors to assist with specific challenges.
Clean Growth Fund is a £101m venture capital fund investing in and supporting companies that are actively contributing to reducing greenhouse gas emissions or improving resource efficiency. CGF will invest across the technology spectrum, including hardware, software, process systems, materials, deep tech and business model innovations capable of driving real and rapid change on a global scale.

CGF’s core focus is companies with outstanding management teams which have a pilot or alpha prototype that successfully demonstrates the technical feasibility of their product or service alongside compelling evidence of market engagement.

Typical first round investments are in the region of £0.5-3m and CGF actively participates in follow-on rounds so the overall investment in a company can be much higher.

Clean Growth Fund
cleangrowthfund.com

Contact:
info@cleangrowthfund.com
Concept Ventures is the UK’s largest dedicated pre-seed fund. Through a people-centric investment approach, we back founders at the earliest stages of their journeys, supporting them in building globally impactful companies. We are specialists in the first 12-18 months of your journey.

We look for exceptional founders; which means unique domain expertise, strong founder working histories and execution-centric approaches to company building. We are sector-agnostic software investors and mainly look to invest in companies rethinking how we work, learn and play.

Our value add is helping our portfolio go from pre-seed to Series A, thereby bypassing the seed round. We have already seen strong traction from our portfolio who have raised Series A from prominent investors such as a16z, Index and more.

Concept Ventures
conceptventures.vc

Contact:
hello@conceptventures.vc
Cornerstone VC is an early stage VC firm focused on a 'people first' investment strategy. We provide pre seed / seed capital to high growth UK tech businesses led by diverse founding teams.

Our typical investment size ranges from £250k to £1m.

We primarily focus on:
- UK headquartered startups
- Led by diverse founding teams
- Pre seed (post MVP) or seed (post traction)
- Tech enabled.

Cornerstone VC
cornerstonevc.co

Contact:
team@cornerstonevc.co
Cottagequinn Enterprises Ltd is the family office investment company whose focus is investing in the future of a sustainable food supply chain, with investment in both early stage and established agri-food and agri-tech companies.

The company is led by Jim Dobson OBE, former Chief Executive and Chairman of Dunbia, one of the largest meat processors across the UK serving markets including major UK and EU retail operators, foodservice and commercial sectors. Establishing Dunbia over 40 years ago, Jim co-founded the company with his brother. During this time Jim’s entrepreneurial vision and strategic leadership led the growth and development of the company from a small butchers shop to a highly respected and successful business operation turning over £700m and employing over 4,000 staff. In 2017, the business merged with Dawn UK to become a £1billion turnover company.

The Cottagequinn team has over 100 years combined experience working in agriculture, food production, FMCG and international sales. The team offers a wide spectrum of support and guidance based on the specific needs of the investment target including Sales, Marketing, Operations, Strategy and Finance.

Having engaged the team are now seeking to share their expertise and experience gained over the years in the food supply chain sector and provide both financial and entrepreneurial support to up and coming business throughout all aspects of the agri-supply chain. We believe in creating value added partnerships through financial and intellectual support in forward-thinking, innovative businesses.

We understand the highly specific needs of emerging businesses. We have built our foundations on providing the right resources that enables access to the relevant customer markets and delivers sustainable growth into the future.
Launched in February 2021, Counteract was the world’s first dedicated carbon removal/sequestration venture capital firm. We intend to catalyze 5 GtCO2e of carbon removal by 2050.

We write first cheques at pre-seed and seed stage of £100k - £1m with the capacity to follow on up to and including Series A and up to £2m in aggregate in any individual company.

Counteract’s team has 70+ years as entrepreneurs in diverse sectors (fintech, media, technology, biogas, aluminium recycling), growing businesses from startup to global. We have experience of 50+ deals from every side of the table.

We now turn our experience to helping early stage entrepreneurs succeed in the nascent carbon removal market, which is expected to grow to $1+ trillion by 2050. Alongside leveraging our entrepreneurial experience we also act as guides to and influencers within the evolving carbon markets.

Current details of how to submit investment opportunities to us can be found on our website at: counteract.vc/contact
CPT Capital is defined by the companies we invest in. We partner with the best and the boldest companies driving the food technology revolution. From plant-based proteins to recombinant proteins to cell-based meat, we back the most promising solutions from pre-Seed and Seed all the way through to sale or IPO and longer term.

Our investment criteria is based on backing teams and ideas aiming to revolutionise global food production at the earliest possible opportunity. Specifically, CPT Capital is looking for companies that are seeking to directly replace an animal-derived product and have strong technical barriers to entry or an IP-protected element.

We make investment decisions based on the potential for transforming the current food production system, as well as the potential to achieve extraordinary capital growth.

CPT Capital LLP
cptcap.com

Contact:
lesley.farrah@cptcap.com

We look to invest as early as pre-Seed and Seed stages and are open to opportunities across the globe. We are looking for passionate and dynamic founders with a strong vision and mission alignment to drive the future of food.
Creative UK champion, connect, support and invest in creative people and businesses. We’re a group of diverse and inclusive professionals who believe in the power of the Creative Industries to change lives, placing creativity at the heart of the UK’s culture, economy and education system.

Our goal is simple: to cultivate a world where creativity is championed, valued, and fundamentally nurtured.

We unite the Creative Industries and generate opportunities for innovation to thrive by investing in people and their ideas. We are here for those who dare to imagine a fairer, more prosperous world, achieved through the power of creativity.
Creator Fund is a leading early-stage investor in university-founded companies across the UK. We invest in start-ups that include a PhD graduate, academic, or recent university alumni as part of a founding team.

We invest in companies with a PhD, academic, or student founder. The founders we back are pursuing research across the following disciplines:

- Artificial Intelligence
- Life Science
- Robotics
- Advanced Materials
- Applied Physics (Quantum Computing, Photonics).

Creator Fund was built to help scientific founders take ideas out of the laboratory and turn them into businesses solving major commercial challenges. Since 2020 we have invested in 26 start-ups. We back technical founding teams when they are uniquely qualified to win in a space and invest in markets where technological innovation is likely to be the key competitive differentiator.

Our portfolio includes companies working on artificial intelligence safety, advanced drug discovery platforms, mutation-proof vaccines, and drone logistics software for healthcare. Our portfolio is available on our website below.

We are uniquely placed to connect high-calibre talent into our portfolio with more than 30 PhDs across over 25 universities in the UK & Europe on our team.
Deepbridge Capital
deebridgecapital.com
Contact:
funding@deebridgecapital.com

Deepbridge operates 4 EIS/SEIS Funds across the technology and life sciences sectors; Deepbridge Technology Growth EIS, Deepbridge Life Sciences EIS, Deepbridge Innovation SEIS and Deepbridge Life Sciences SEIS.

These Funds allow Deepbridge to fund companies from pre-seed to Series A stage, with recognition of the importance of continuity of capital to the journey of such companies.

At the pre-seed/seed stage, we seek highly disruptive companies with sector expert founders, with a clear opportunity to scale and protect IP. At EIS stage, we expect companies to have a degree of traction. This could be initial commercial revenues, a key strategic partner or clinical buy-in, depending on the sector.

Sectors we have invested in include FinTech, automotive tech, sustainable tech, drug discovery, therapeutics, healthcare tech, medtech, AI, VR/AR, Blockchain, space tech, biotech, Agritech and more.

Dealflow is sourced from numerous partners and contacts, with spinouts from 17 different universities within the portfolio.

Using a clear rating system, linked with our ESG screening, all deals are evaluated on a quantitative basis, with value proposition, IP and team experience key drivers. This is supported by other factors relating to competition/disruption of the innovation, scalability, commercial traction and future exit opportunities. We also have metrics and a review process in place to minimise any unconscious bias and reward gender and ethnic diversity of the founding team.

The Deepbridge approach to supporting investees has always been focused on providing practical, hands-on guidance and management. This may include supporting the founders to develop a C-suite and Board with the necessary skills and experience. Our focus is then to ensure companies have robust governance and reporting, with a future eye always on ensuring companies are investor ready and able to attract co-funding – with syndication a key priority.

Depending on requirements, our team will provide commercial guidance to scientific-led founders and provide specific support including sales and marketing support, website development, accounting guidance and strategy input. Our key role is to provide both backing and to challenge management teams ensuring that the appropriate focus is adopted, which can often mean identifying the appropriate use or market for an innovation. Whilst syndication on deals is important, Deepbridge prefers to lead rounds in order to ensure that our active management style is adopted.
Deep Science Ventures invests in high impact companies which we have built in-house and with strategic partners, using our unique innovation methodology.

We focus across 4 main sectors:

- Climate
- Pharmaceuticals
- Agriculture
- Computation

We co-invest with financial and industry leaders into these companies at spin-out/pre-seed stage and follow on at seed stage in 20-30% of portfolio companies.

Investment Criteria:

- Impact against top level outcome - e.g., global temperature or curative potential.
- Team - ability for team to deliver against key outcomes to impact and to overcome likely blockers.
- Technology - time to TRL 9 (Net Zero) or to patient impact / clinical POC (Therapeutics) and to intermediate milestones on the development path, Technology capable of solving impact and customer/patient outcomes provided it follows predicted de-risking path, inherent tech risks are addressable through detailed and executable POC workplans.
- Neglected - Novel, Inventive, Freedom to Operate and potential to generate novel IP, compounding effects in business model / product design.
- Value Capture - High margin unit economics (Net Zero), cost-benefit clearly defined (Therapeutics), primary and secondary market (patient) segments identified, evidence of initial interest in partnership / collaboration / sales, business model is well-defined.
- Market - customers accessible through proven repeatable route to market, growing market or market with substantial unaddressed needs, market meets minimum scale criteria, scaling is not prohibited by external factors (e.g., materials or regulatory environment).

The value we add to investees:

- We build deep relationships with our founders.
- Community - we have community events within and across different sectors to bring people with similar mindsets together and to enable: problem solving, talent referrals, collective ideation, ongoing investment connections, industry input, operational advice.
- We offer direct investment to companies we have built as well as working with our wide network of investors and industry contacts to enable additional investment ranging from angels and early funders to top tier firms, and to introduce/support meaningful partnerships and collaborations.
- We have a deep understanding of teams and their technology and can help with very detailed problem solving.
- We provide connections with potential customer groups, advisors and mentors.
Deeptech Seed Fund leads funding rounds in companies just as they are spinning out from university or research.

We invest in non-life-sciences companies provided that they have good evidence that some early adopters are going to be willing to do business with them. We are unusual in that we will work extensively with ventures before they are otherwise investor-ready and before they spin-out, provided they have strong evidence of demand.

Innovate UK’s ICURe programme and several incubators across Europe and are using our Deeptech Seed Fund Scorecard.

Deeptech Seed Fund
deeptechseedfund.com

Contact:
info@deeptechseedfund.com

We work closely with deeptech incubators, specifically with ones that do a really good job of customer-discovery/market validation.
The Development Bank of Wales is committed to driving innovation and growth. We provide investment into new and established innovative businesses with the purpose of unlocking potential in the Welsh economy. We are well capitalised to support exciting new investment opportunities across a range of sectors including life sciences, med tech, next generation digital technology and green innovation.

We work closely with our investee companies offering a partnership approach to maximise success. We do this through a focus on value-add activity with our investee businesses managed through a dedicated contact. This may include referrals for dedicated business support, linkage with a mentor or Non-Exec director, a large network of co-investment partners and capacity to provide follow on funding.

Our investment ranges are typically £50k to £450k for early-stage investment, rising to over £2m for venture investment. Our product range works as a funding escalator able to address business needs at each stage of their growth, providing accessible follow-on investment. Through the investor programme we are therefore well placed to support businesses with feasibility study projects, industrial research projects and experimental development projects.

As an organisation for economic development in Wales the businesses we support must be based in Wales or be able to demonstrate the majority of their economic impact is in Wales.
DSW Ventures operates from Manchester with an investment thesis to invest across the UK regions outside the Golden Triangle, bridging the gap between friends-and-family investment through to Series A funding: a yawning gap for regional scale-ups.

We invest in early stage technology-based businesses and university spinouts with up to £1m per round, usually leading syndicates to deliver much larger sums as needed.

We are a thorough and very hands-on investor, offering huge amounts of support to our investee companies.

DSW Venture Capital LLP

dsw.vc

Contact:

hello@dsw.vc
Earlymarket LLP is a London-based family office with an investment arm dedicated to early-stage technology start-ups. Founded by Patrick Wills and Sarah Wills, Earlymarket has been formally investing since 2015. We deploy capital of £100–£150k, along with potential follow-on capital. We focus on key investment themes including Energy Transition, Personalised Healthcare, Future of Agriculture, Healthcare Data and Delivery, Data Privacy and Security, and Smart Contracts.

Since 2015, we have successfully exited 5 companies and currently have a portfolio of 10 companies. Both Patrick and Sarah are experienced entrepreneurs, who bring a wealth of knowledge and support for companies. We understand the challenges involved in bringing a product to market and scaling it. We are hands-on, supportive, and impactful as a family office. To have the biggest impact we believe in partnering with start-ups at the earlier stages of start-up development, between Seed and Series A.

We nurture close relationships with our portfolio companies and offer guidance to founding teams on areas such as, fundraising, human resource and recruitment, commercials, governance, and strategy. Where possible, we maximise our network of advisors, investors, and commercial contacts.

We typically look for UK opportunities with S/EIS eligibility and within high-growth markets. As thematic investors, we prefer our investments to align with one of our investment areas. We also usually look for evidence of potential product-market fit. Start-ups do not have to be revenue generating, but an MVP and potential upcoming traction is attractive. We look for an exceptional founding team and a strong board of advisors.

If you are a motivated founder whose company aligns with our investment thesis, we would love to hear from you. Please visit our website for more information.
Earth Capital is an early-stage growth manager, investing across the UK and Europe in clean technology solutions within the energy, food, and water sectors. We lead co-investment rounds of typically £3-8m with the potential for follow-on funding.

Our investment team professionals are experienced in active and value-add portfolio management, with strong track records that enable value creation and avoid first-time errors. To support our portfolio, we take a NED position on the companies’ boards, as well as an observer role, which allows us to bring in area-specific experts as needed to support the company’s development.

By selecting sustainable development as our investment theme, we address social and environmental challenges and partner with our portfolio to consistently improve their performance in this area. Through our award-winning Earth Dividend™ portfolio management tool, we seek to have a holistic overview of a portfolio company’s contribution across ESG and focus on the connection between positive impact and commercial value, ensuring continuous performance improvement.

Our criteria for investment includes:

- At least £1m annual revenue (excluding grants) with proven repeat sales
- Management based in the UK or Europe
- Proprietary and defensible IP
- A clear and established product market fit
- Clear plans for expansion and growth
- A net positive environmental impact.

If you are an innovative founder of a company that meets our investment criteria, we invite you to connect with us. Explore our website for additional details.
East Innovate is a London based venture capital firm that invests in early-stage businesses developing advanced technologies in resource and energy systems. It is the venture capital arm of East Alpha, a quantitative commodity technology and research company.

We look for early-stage companies working in three focus areas:

1. Electrification and Future Commodities
2. Energy Efficiency, Waste and the Circular Economy
3. Supply Chains, Markets & Information Systems

Within these focus areas we invest in companies with breakthrough products that have the potential to rapidly grow high-value long-lasting positions in growing international markets while providing material and positive impacts to multiple sustainable development goals.
Ebico Innovation is run by a group of seasoned entrepreneurs and executives driven by a shared passion for fostering the success of outstanding ideas with a positive social impact. Our focus lies in supporting determined teams with a well-defined vision for expanding their businesses and making sustainable, affordable warmth accessible to more households.

We focus on companies that:

- Create a genuine positive impact on the affordability and accessibility of household Net Zero living
- Demonstrate high growth potential
- Possess a product or service with distinctive intellectual property, either in development or as a Minimum Viable Product (MVP)
- Have a clear exit strategy in place
- Are co-founded by a minimum of two dedicated entrepreneurs.

Ebico Innovation engages in Seed and Early Stage Investing, offering both debt and equity financing options.

Regular communication and feedback are integral to our approach, leveraging the extensive experience of our seasoned executives.

With expertise in investment management and extensive experience in the UK’s energy retail sector, issues around fuel poverty, corporate finance and funding, we bring our own unique expertise in social impact entrepreneurship to the table, further enhancing the support we provide to the ventures we back.

Investment application.

Ebico
innovation.ebico.org.uk

Contact:
innovation.ebico.org.uk/contact-us
Eka Ventures invests in companies building a more healthy, sustainable and inclusive economy.

We have two main focus areas:

**Sustainable consumption**
Shifting to an efficient, circular model that delivers products that are better for the consumer and the planet.

**Consumer health**
Moving from a reactive treatment-driven health system to a more proactive, inclusive and preventive consumer-led system.

There is an open application process for founders: [ekavc.typeform.com/submit-pitch](http://ekavc.typeform.com/submit-pitch)

If you are not yet ready for this, the best way to get in touch with one of the team is via their emails on the website.

Eka seeks to assist portfolio companies from a strategy, network, talent and fundraising perspective.

EKA Ventures
[ekavc.com](http://ekavc.com)

Contact:
[ekavc.typeform.com/submit-pitch](http://ekavc.typeform.com/submit-pitch)
Elbow Beach Capital backs early-stage businesses whose technologies have the potential to solve our planet’s biggest challenges. We target long-term value creation, whilst working with founders and entrepreneurs to accelerate the development and implementation of positive impact technologies.

We look for early-stage ventures, typically with capital needs between £0.5 million and £1.5 million, who are developing unique and scalable solutions to significant environmental or social problems. Beyond technology, we also place a strong emphasis on market fit and team, supporting start-ups with strong governance and company ethos, but also with commercial viability and a clear runway to financial growth.

Value added:
We pride ourselves on actively engaging with and supporting our investee companies through every stage of their growth and development; and ultimately through exit. We win as a team. Science-led entrepreneurs often do not yet have the commercial insights to develop and promote their concepts; Elbow Beach Capital acts as a catalyst in converting complex concepts into commercial realities. Our business acumen combined with the environmental science background of our CTO allows us to deliver significant value-add on an accelerated time scale.
Elsoms Seeds is the UK’s leading independent seed specialist and plant breeder. We breed, supply and treat high quality vegetable and agricultural seed throughout the UK, EU and North America, using the latest in plant breeding research and seed technology. We are passionate about contributing to feeding the world and improving the environment. As well as our plant breeding and seed technology businesses we also contribute to these goals by investing in Ag Tech start-ups.

Established in 1844, Elsoms has remained an independent family-owned business throughout its history and continues to develop as the leading plant breeding specialist and trusted supplier of top-quality seed in the UK. We are passionate about seeds. Throughout the long history of the company, the professionalism and teamwork of our specialist staff has ensured that Elsoms always provide excellent service. We also work alongside top UK plant research institutions and our partners, enabling us to adapt and fulfil the changing demands of customers.

As the UK’s leading seed specialist, we are continually fighting disease and other issues facing growers. With our own plant breeding programmes and seed treatment facilities, we can provide our customers with the best possible products. Across our four key business activities, vegetable seed, agricultural seed, seed treatment and breeding, our experienced staff provide suppliers and customers with a high level of expertise and support for which Elsoms have become renowned.

We work closely with a wide range of major UK and international companies and our reputation for professionalism ensures we maintain our valued, long-term partnerships to continue benefitting our customers and partners.
Eos is a hands-on, early-stage investor into science and technology innovations that seek to address societal and environmental issues.

With deep roots in Scotland and a global mindset, Eos is a leading investor within four impact areas:

- Disease, diagnosis, prevention and treatment
- Food and water security
- Energy security, climate change & pollution
- Improvement and sustainability of industrial processes.

Eos has sector specialism and a strong track record for understanding the risks of investing in knowledge intensive companies.

Eos is regulated and authorised by the FCA.

Further details and a contact form available at eos-advisory.com.

Contact:
innovate@eos-advisory.com
Epidarex Capital is a venture capital firm led by a diverse team of early-stage investors building breakthrough life science companies in emerging hubs within the UK and US.

Our aim is to build extraordinary companies that transform novel science into the next generation of highly successful drugs and medical devices. As founding investors, we provide seed or Series A funds and have a strong track record of attracting follow-on investment from top tier funds.

We often partner with leading universities and research institutions to provide much needed capital for their most innovative ideas.

We invest in most areas of life science including biotechnology and pharmaceuticals, medical devices and health tech.

Key factors that we consider in our evaluation include:
• Disruptive platform technologies that address large and unmet medical needs
• Novel innovations that offer a sustainable competitive advantage
• Future pipeline of high value products deliverable to the patient or customer
• Robust Intellectual Property portfolios (patents, trade secrets and “know how”)
• Prospective commercial partners and early evidence of market validation
• Early traction and support from key opinion leaders and health practitioners
• Clear regulatory (and where applicable, insurance reimbursement) strategies
• Efficient use of capital
• Highly driven and tenacious founders and entrepreneurs
• Potential for outstanding financial return and significant patient impact.

Our international management team has a track record of successfully partnering with scientists and entrepreneurs to develop highly innovative products for the global healthcare market. We leverage our extensive relationships, industry operating experience and a disciplined investment approach to add significant value to our portfolio companies and to generate strong returns on investment for our investors.
Equity Gap is a member-led angel syndicate established to help match investors with entrepreneurs looking for early stage business funding.

Equity Gap members are prepared to invest in any SEIS/EIS eligible sectors, with the individual decision to invest driven by factors including prior knowledge of the sector, how the company’s proposition solves customer problems, the commercial opportunity and traction achieved, the business’s willingness to work with investors and critically the founder team experience and capability.

The existing portfolio are all companies using disruptive technologies to meet customer and societal needs, in areas such as digital services, manufacturing processes and widening access to clean technologies.

Equity Gap supports most portfolio companies with an Investor Director from our member base, appointed by mutual consent to the board, and a board observer who is a member of the Equity Gap team. Investee companies benefit from mentoring and knowledge sharing by our diverse and accessible cohort of investor members, many of whom are exited founders; company leader peer events to build networks and share best practice; access to data, insight and reporting tools and ongoing input from Equity Gap’s experienced team. Prospective investee companies can find out more about Equity Gap’s criteria, process and portfolio at our website.
Extantia Capital is a climate-first venture capital firm accelerating the path to a decarbonised world.

Extantia unites mission-driven entrepreneurs, scientists, investors, and business leaders to advance the transition. The platform includes Extantia Flagship, a fund backing scalable deep decarbonisation companies, Extantia Allstars, a fund-of-funds investing in climate venture capital funds, and Extantia Ignite, a sustainability hub advancing knowledge and competence in climate innovation and ESG practices. For more information, visit www.extantia.com.

Contact:
innovateuk@extantia.com
Fearless Adventures - Shaping a future where fearless entrepreneurship thrives.

Here at Fearless Adventures, we like to do things differently.

We are built by founders, for founders, and through our unique investment model, we aim to accelerate a company’s growth trajectory to help the founder achieve a market-leading exit.

The genesis of Fearless Adventures came from our frustration as founders ourselves: building, scaling, and exiting our own businesses while working within the confined boundaries of a rigid investment landscape, whereby investors provided little support outside of money alone. In response, we’ve built an investment model that provides a platform of genuine support, helping founders to tackle the ever-growing list of challenges that come with scaling a business. Investment through Fearless Adventures brings not only capital but also mentorship from experienced entrepreneurs, omni-channel marketing expertise from industry specialists, recruitment support to help build a team, warehousing and fulfilment services, financial accounting, and strategic exit planning.

Our first-hand experience in scaling and exiting some of the most exciting brands in the UK has led us to focus our investments on the e-commerce, technology, and consumer landscape, with a passion for supporting founders from under-represented groups and those looking to leave a positive impact on our planet. We’re proud to share that 33% of businesses in our existing investment portfolio are female-founded, 55% are female co-founded, and 89% of businesses are based in the North of England, a region that has historically been under-served by the investment community.
The Foresight WAE Technology fund (“FWT”) is a unique collaboration between Foresight Group and WAE (formerly known as Williams Advanced Engineering). The fund combines Foresight’s proven investment management experience with WAE’s engineering and technology expertise, derived from decades in the ultra-competitive environment of motorsport.

FWT invests in IP rich, seed stage, deep technology/advanced engineering businesses whose technology offers an order of magnitude improvement over the status quo. The fund typically invests £0.5m-£2.0m initially, with significant capital to follow-on. All our portfolio companies receive technical, commercial, and promotional support from WAE, which we believe is a unique offering in the market.

Foresight Group was founded in 1984 and is a leading listed infrastructure and private equity investment manager. With a long-established focus on ESG and sustainability-led strategies, it aims to provide attractive returns to its institutional and private investors from hard-to-access private markets. Foresight manages over 330 infrastructure assets with a focus on solar and onshore wind assets, bioenergy and waste, as well as renewable energy enabling projects, energy efficiency management solutions, social and core infrastructure projects and sustainable forestry assets.

Its private equity team manages over 20 investment funds across the UK with ticket sizes ranging from £250k to £10m with the majority between £1m and £5m. This team reviews over 2,000 business plans each year and currently supports more than 200 investments in SMEs. Foresight operates from 16 offices across seven countries in Europe and Australia with AUM of £12.6 billion (unaudited AUM as at 30 September 2022). Foresight Group Holdings Limited listed on the Main Market of the London Stock Exchange in February 2021.
FOV Ventures is a specialist early-stage fund investing in founders building startups that leverage next generation technologies such as extended reality, spatial computing, artificial intelligence and the metaverse. We invest up to £500k, primarily in pre-seed and seed rounds.

As a specialist investor we only invest in startups where we believe we can deliver a true value add. This value add comprises of our deep sector expertise, global network and our extended ‘Edge Network’ made up of senior leaders from key players in our sector.

Startups can submit their information at fov.ventures/contact-us.
UKI2S invests at the very early stages in “deeptech” companies based on highly innovative technology, often emerging from the UK’s publicly funded science and knowledge base and in particular from the partners in the fund, who include several of the key funding bodies in UK science, including UKRI, Dstl and DSIT.

Although we are entirely funded by public entities looking to support and enhance innovation in their spheres, we operate on very similar lines to most venture capital firms, though with a higher appetite for early-stage risk than most venture firms. We are usually the lead or co-lead investor at the pre-seed and seed round stage, and almost always expect to play a substantial role at board level for at least the first couple of years, helping to build out the board and management team, as well as building the funding strategy and helping source further investment for later investment rounds.

We are a long term and supportive investor with a substantial portfolio of existing investments, some of which we have held for over 15 years. We invest across a wide range of technology areas but have a particular interest in engineering biology companies (including those with in silico products), companies developing fusion energy technologies, and companies developing “dual use” technologies with applications in both defence & security and civilian markets.
GC Angels is a seed fund investing primarily in future economy startups in Greater Manchester (GM). We are part of the Growth Company, a not-for-profit employing ~1500 people to provide support nationally.

By leading seed investment rounds and using our network of private investors to leverage up the capital, we enable high-growth startups to access the capital required. We have been investing since 2018 and typically invest £50,000-£150,000 in investment rounds. We are focusing primarily on the Future Economy, focusing on Net Zero, Next Gen Digital Technologies, and Know No Limit businesses. Upon investment, GC Angels take a board observer position and provide support throughout the startup journey.

GC Angels has a proven track record of success with this operating model typically leveraging more than 3x private investment at investment and generating a 40% follow-on investment rate in our 36 portfolio companies. Notable recent co-investment partners include HNWIs, Haatch and Green Angel Syndicate.

Through our internal and external support systems, we augment the startups we invest in with valuable services that enable their transition into high-growth, international scale-ups. Across 36 portfolio companies, we have achieved several exits in 2023.

Internal in GC, we can access support packages in employment and skills, PR, marketing, exporting, green economy/sustainability, and export/growth loans. We are partnered with 30 innovation sites, ~75 active Angel investors, 20 co-investment funds, and 10 startup service companies offering bespoke discounted services. Built from the ground up, we have encased our portfolio with all the support necessary to scale. Recent exits and follow on investment rounds showcase the value add we inject in our investees and the success this generates.

Our experience investing in companies delivering social, environmental, and economic impact, is well established. Our recent investments reflect our commitment. Financielle are a FinTech company focusing on financial education for women, a highly underrepresented sector in the market. Vector Homes are using sustainable materials to build the homes of tomorrow. And Molymem are developing world-leading nanofiltration for water systems around the globe.

GC Angels is a committed diverse investor. We have a well-developed network of ecosystem partners that bring a hugely diverse deal flow and co-investment opportunities. We assess all opportunities equally and our proud of our track record in supporting diverse founders.
Green Angel Ventures is the reference early-stage investor for UK climate innovation. We welcome funding applications from early-stage companies that are committed to addressing global warming and climate change challenges. This includes companies focused on reducing or reversing greenhouse gas emissions or preserving and restoring the natural environment.

Our investments are primarily targeted at resource focused ventures in key sectors, which include Energy, Transport, Buildings, Food and Agriculture, Industry & Recycling, as well as Carbon Removal and Nature based Solutions.

At GAV, we are particularly enthusiastic about fostering diversity and encouraging applications from founders representing minority groups.

GAV’s value to investee companies is exceptional, due to our 350 specialist members’ deep expertise in critical climate change sectors.

We appoint experienced non-executive directors post-investment, offering invaluable guidance and leveraging their extensive knowledge to aid companies in seizing opportunities and overcoming challenges. Our specialisation in climate innovation distinguishes us, providing more than just financial support. We offer a distinctive combination of industry knowledge, rigorous due diligence, and ongoing mentorship. Our commitment extends beyond funding, making us a valuable partner in your quest to combat climate change and foster sustainable growth.

Companies considering Green Angel Ventures for funding should meet the following investment criteria:

1. The company must have an innovative product or service which is able to demonstrate its effect in tackling climate change. This includes tangible impact such as nature-based solutions, biodiversity improvement, etc.

2. The company should be eligible for the Enterprise Investment Scheme (EIS) - in other words, UK-based and eligible for advance assurance by HMRC (although this does not need to have been received before you apply).

3. The company must have a targeted Exit plan within 3 – 7 years.

4. The company must be investor-ready, with a business plan, financial projections, an established team, evidence of demand, a clear competitive advantage and protectible IP.

5. The company should have developed its product or service to at least MVP stage, or in Technology Readiness Scales (TRL) 5 or above. The company can be pre-revenue.

6. We typically invest between £200k and £1.5m ourselves, we often co-invest alongside other professional investors and are happy to lead or follow.
Henley Business Angels (HBA) is an Angel Network based out of Henley Business School. Established in 2016, HBA exists because of its members, who support entrepreneurs through a combination of investing and mentoring. Members of Henley Business Angels represent a cross section of business leaders from the communities of the University of Reading and Henley Business School, including successful entrepreneurs, MDs/CEOs, partners, chairpersons and NEDs of private and public companies.

Central to Henley Business Angels’ core mission of investing in entrepreneurs is to support their professional and personal progression, as well as provide mentoring and coaching. Entrepreneurs that are successful in being considered for investment are invited to Henley Business Angels’ highly regarded day-long Investment Readiness Workshop, for entrepreneurs to gain invaluable knowledge and advice to further expand and develop their business. Areas explored as part of the required workshop include pitching for investment, financial management, legal, IP strategy, accounting, HR, and more. Henley Business Angels accepts applications from companies in most sectors, however, science and technology innovation-based businesses are preferred.

Certain sectors like arms & weapons, fossil fuel exploration and tobacco will not be considered. Henley Business Angels typically look to invest in companies that are:

- Registered in the UK
- Raising £50k - £500k
- SEIS/EIS advanced assured
- Strong management team

- Ability to show how funds will be used for growth
- High growth potential
- Sustainable competitive advantage.

Henley Business Angels’ full Investment Criteria can be found here: henleybusinessangels.com/investmentcriteria/

Henley Business Angels investors provide a vast range and high level of expertise to their investments, with several HBA members taking on roles as NEDs and specialist advisors within their investment once they’ve invested. Henley Business Angels members do not just invest financially, but also their knowledge, time and experience to support entrepreneurs and their growth strategy as effectively as possible. Furthermore, being based out of a world-renowned business school allows HBA to provide a vast network of academic, professional and business contacts. Not only this, but The University of Reading’s Entrepreneur in Residence, Professor William Kilgallon, is also one of the network’s most active members and chairs the company presentations session at HBA’s quarterly Company Presentations Event. Entrepreneurs interested in speaking with Henley Business Angels are advised to contact Chris Rees, Director of Henley Business Angels, at entrepreneurs@henleybusinessangels.com.
HERmesa is a women-led angel syndicate in the UK backing female (co) founded ventures at pre/seed stage.

HERmesa is sector agnostic, however, we require women (co)founders to hold at least 20% equity and to have meaningful decision making roles. We strongly prefer digital technologies / IP led investments vs product companies. We do not invest in med / bio-tech or therapeutic startups.

HERmesa investors typically invest between £50-£150k/company and we invest collectively, grouping all interested investors under a nominee framework.

HERmesa
hermesa.co.uk

Contact:
airtable.com/shrs6fTceS6ON8nCB
HG Ventures is the corporate venture capital arm of The Heritage Group (THG). It supports innovation and growth by investing and partnering with private companies developing new technologies and approaches in THG’s core and adjacent markets. THG’s purpose is to build a safer, more enriching and sustainable world by harnessing the power of family. By leveraging the world-class expertise of THG operating companies and research centre, HG Ventures offers a unique value proposition to its portfolio company partners.

HG Ventures invests in early stage and growth stage companies developing advanced materials and systems for transportation infrastructure, environmental services and specialty chemicals. We will invest at the pre-revenue and pre-product stage, but we want to see the beginnings of a dedicated, full-time executive team. We are based in the United States, and we have made multiple investments in the UK and look forward to helping more UK-based companies grow in the UK and expand to the United States if appropriate.

Generally, HG Ventures will invest up to $20 million in each portfolio company, but we have the ability to invest more depending on the opportunity. We are flexible with regard to initial investment amounts, including participation in relatively small financings. We take a long-term approach to building value. We focus on value creation milestones with no fixed expectations for liquidity.

Our team has the capability to lead and structure financings, but we will also follow other investors into a syndicate. We will be actively involved in helping companies grow and will take board seats when appropriate.

We apply strict confidentiality policies and procedures to protect private company information. All proprietary information is secured within a small, defined group of HG Ventures professionals and is not shared with others in THG unless authorized by our entrepreneur partners.
Hiro Capital is a London / Luxembourg based Technology Venture Capital fund that invests globally in Games, IP, Spatial Computing and Metaverse and Technologies. Hiro Capital invests at Seed through Series B stages and backs experienced entrepreneurial teams, building innovative technologies and content with a strongly differentiated proposition and with the scaling opportunity to become very large.

The Hiro Capital team are Games and Technology investors who are also Games and Technology entrepreneurs. Hiro Capital’s core belief is that Videogames, Spatial Computing Technologies, Creator Platforms, and Digital Sports will be a central pillar of Entertainment, Economic, and Social Life in the mid-21st century. Hiro invests in the innovators who are building that future.

Hiro was founded by entrepreneurs that have been there before and carry the scars of building successful businesses. The whole team is very operational and we put our expertise at the service of the companies we invest in, whether it’s strategic advice, building a business plan, needing introduction from our vast global network in the industry, etc. The Hiro team have co-founded and angelled over $9 billion worth of some extraordinary games, sports and technology companies.
IP Group develops world-changing science and technology businesses across life sciences, technology and cleantech (through Kiko Ventures). The Group has a strong track record of success, having been the founder investor in a number of high-profile companies including Oxford Nanopore Technologies plc, and has one of the most exciting portfolios of high-growth businesses in Europe. The Group also owns Parkwalk, the UK’s largest growth EIS fund manager which backs world-changing technologies emerging from the UK’s leading universities and research institutions.

We’re one of the most active investors in university and other research-based companies in the world, with a proven track-record in backing and nurturing science and technology-based businesses to deliver impact alongside returns. We’re committed to backing and supporting businesses that bring about a better future for people and planet - companies whose products and services meaningfully contribute to a healthier, tech-enriched; and regenerative future.

Since pioneering the IP model more than two decades ago, we’ve built up a considerable knowledge bank and honed our approach to ensure all stakeholders benefit from the work we do through our portfolio companies.

Why IP Group?
• Track record
• Portfolio – access to the best science
• Permanent capital structure

Key Figures:
• IP Group has been a leading driver of scientific investment for over 20 years. We have invested over £1.2 billion in UK early-stage scientific development, fueling the creation of three unicorns, and helping the companies we have backed to create more than 10,000 jobs
• IP Group owns Parkwalk, the UK’s largest growth EIS fund manager, which has raised over £400m and backed more than 150 university spin outs across the UK
• Together, we work at the cutting edge of life sciences, deeptech and cleantech. We’re scientists, innovators and practitioners with in-field experience and insight
• Together, we have backed over 500 science-based companies which are delivering ground-breaking innovation – from Ceres and Oxford Nanopore, to investments such as Istesso, First Light Fusion, Featurespace and Oxbotica

IP Group Plc
ipgroupplc.com

Contact:
NewBusiness@ipgroupplc.com
IQ Capital is a venture fund based in the UK. We initially invest up to £8m per company from our Fund IV, in disruptive UK based tech companies capable of dominating their global markets. We invest at Seed and Series A, and we’re actively seeking investments in AI, Data Science, Robotics, Computational Biology and more.

We can partner with you throughout your growth – we know that it takes time to develop global markets, and that deep-tech can take longer & cost more than originally expected. We have extensive global connections, and our own investors are themselves committed to science & innovation – from family offices and successful tech entrepreneurs through to institutions including the British Business Bank.

We keep pace with the success of our outperforming businesses, helping to build a robust VC syndicate, and for our part we can invest up to £30m from our IQ Capital Growth Fund, as you raise your later rounds.
Jenson Funding Partners is the approachable startup investment firm specialising in working with founders throughout their early-stage growth from pre-seed to Series A. Its diverse and experienced team understands what a business needs at each stage and combines quickly deployed capital with hands-on support to successfully scale the companies in their portfolio and deliver returns for investors.

An established player in the early-stage VC ecosystem. Having launched one of the first and longest-running SEIS funds, the firm has helped shape the landscape of startup investment over the past decade. The firm is currently undertaking an expansion and creating its first institutional fund, which will continue to support its portfolio companies as they scale.

Jenson prides itself on inclusivity, not exclusivity investing in businesses across a range of industries to create a diverse investment portfolio across sectors, geographies and founder backgrounds. A core criteria is that the founders it backs are experts in their field and through an open ethos it has been able to attract high-performing portfolio companies led by impressive founders. The firm prides itself on its track record of investment into diverse startups, with minority and female-led teams, across the UK.

To date, we have invested across a range of sectors which include:

- EdTech
- FinTech
- VR
- Gaming
- Maritime
- Telecomms.

Our Investment Criteria:

- Management team credibility
- Business and financial risks
- Business Momentum
- Business Concept and Strategy
- Equity deal and exit expectations.

In many circumstances, the investee companies are expected to have some similar key characteristics such as:

- Generating revenues or with a clear path to revenue generation
- High growth potential with the possibility of realising a good return multiple
- Disruptive business models that if necessary can adapt and thrive in a recessionary environment
- Evidence that a prospective investee company’s product or service is innovative and has market potential
- Addressing market gaps and brand lags – with unique and defendable propositions
- Non-capital intensive business models that are both scalable and capital efficient
- Led by an inspiring, energetic and ambitious entrepreneur(s).

Key to our investment criteria is the Support Programme. This provides key financial, technical, operational and sales and marketing support to investee companies from day one, we are not just investing capital. Our investment mandate includes the nurturing of the early stage businesses we invest in.
Kelvin Capital founded in 2009, has invested in 32 early stage businesses. Having spent the first 6 years investing in pre-revenue companies, the investment focus over the last 7 years has moved towards venture growth capital with our criteria of proven technology, market interaction and ability to scale internationally quickly. The core focus for Kelvin Capital is to support globally ambitious companies.

The companies must be UK based, with an ambitious and credible team who are able to demonstrate a minimal viable service or product and are ready to go to market or are currently revenue generating and looking for growth capital. For companies that are based in Scotland and who will provide an economic advantage in Scotland, we can apply for matched funding with Scottish Enterprise as partners of the Scottish Co-investment fund.

We are sector agnostic but look for companies with the ability to deliver aggressive, international sales growth. For the portfolio companies, Kelvin Capital will not only provide investment but will open up their vast network of connections to provide the support needed to deliver the true potential of each business.

Aside from funding, Kelvin Capital work very closely with the company to ensure good corporate governance and ongoing communication to all stakeholders.

Kelvin Capital Ltd
kelvincapital.com

Contact:
theteam@kelvincapital.com
KHP Ventures is the first NHS-backed venture fund in the UK, built through a collaboration between Guy’s and St Thomas’ Hospital NHS Foundation Trust, King’s College Hospital NHS Foundation Trust, and King’s College London. Collectively, these three institutions represent the largest teaching hospital system in Europe, serving a diverse, local population of 2 million residents and a large, international patient cohort.

We invest in world-class clinical innovators and enable adoption of transformative MedTech and digital health solutions at scale, improving health and healthcare. We target investments from Pre-Seed to Series A, though our sweet spot is typically at Seed stage. Our due diligence process brings in clinical, scientific, operational, and policy experts from across the NHS and global healthcare ecosystems to validate each investment opportunity, ahead of taking companies to our expert Investment Committee.

We invest in companies that have the ability to address the quintuple aim of better clinical outcomes, lower costs, improved workforce experience, increased patient satisfaction, and better sustainability. Consequently, our portfolio companies are best-in-class and meet substantial unmet challenges within the NHS. We offer tailored support to each of our portfolio companies across critical growth activities, including:

- Network introductions; to KOLs across clinical, scientific, managerial, operational, and policy domains
- In-house expertise with design and execution of clinical research studies; for clinical validation, health economic assessment, and patient/user feedback
- Co-design of clinical pathway mapping for successful NHS deployment locally, regionally, and nationally; and in non-UK markets
- Engaging wider regulatory and investment stakeholders e.g., collaboration with NICE
- NHS Integrated Care System involvement for understanding how to impact the care continuum (social care to secondary care)
- Support competitive grant applications (extensive in-house track record) for execution within our partner institutions and beyond
- Enabling entry into highly competitive and lucrative markets e.g., unique strategic partnership with Cedars-Sinai Medical Centre in the US.
Kindred invests in pre-seed and seed stage companies. We look for exceptional founders with a depth of insight into a problem that uniquely positions them to build game-changing outcomes. We’re looking for teams who believe they can genuinely change the way the world works with their technology and build a £1B+ company. We don’t require any specific metrics: you do not need a product or revenue yet or a perfectly polished pitch deck.

Kindred has a partner-only model: when you talk to Kindred, you’re talking to a decision maker who will support your company throughout your journey with us. Furthermore, when we invest in your company, you don’t just get access to one partner, you get access to all of the Kindred partners and our community & network. We have a breadth of expertise spanning the UK, US, Europe, and Israel.

Our model of equitable venture means we’re sharing the profits of Kindred with you - the founders that we back. Our unique funding model aligns our interests with those of the founders we support. We also offer hands-on support, tailored training, and access to our extensive network of advisors and co-investors to help our portfolio companies reach their full potential. You can read unfiltered reviews of us (from our portfolio founders and founders we’ve turned down) on Landscape: www.landscape.vc/investors/kindred-capital

We are a UK and Europe focused fund, with investments in the UK, Europe, and Israel. We invest in tech companies across all sectors. Our current portfolio includes techbio, cybersecurity, enterprise SaaS, fintech, future of work, mobility, automation, among lots of others. A few examples of these are as follows: Cradle, Shift BioScience, Paddle, Fung Money, Hofy, Natter, Dexory, and RobCo.
Our funding is for Liverpool City Region (LCR) based startups. We focus on two sectors specifically:

1. **Health and Life Science sector**: we typically invest in innovations at Technology Readiness Level (TRL) 1-5 with investments from £25,000 up to £250,000 (relative to the TRL)

2. **DeepTech**: we invest in research led spin-outs of DeepTech innovations (including physical science, materials science, data science, artificial intelligence, advanced engineering, advanced manufacturing, robotics, autonomous vehicles etc.) with investments from £25,000 up to £100,000

Our goal is to provide valuable start-up funding and commercial advice that helps clinicians, academics and entrepreneurs in these key sectors to develop their ideas and improve the region’s health and economic outcomes. We invest in innovation focused companies with roots in the region and the potential to grow and create high value jobs.

We have a team that can provide business support services and ensure start-ups are connected to the vast array of other support and funding opportunities available to them, but that may be difficult to identify or access. We proactively support our pipeline to apply for grant funding, as we recognise the high risk and limitations of the funding we can provide.

In addition to providing early-stage investment, we support start-ups with market research, competitor analysis, investment readiness and exploitation plans and link them to others for financial, regulatory and IP advice. We also facilitate access for SMEs to local research and innovation assets to establish collaborative R&D partnerships.
LVP is an early-stage fund with a valuable difference: we’re operating experts in the games ecosystem. The team has been seed investors in game companies that have created over $30 billion in value through exits including Supercell, Unity, Playfish and NaturalMotion. LVP has invested in many other great companies including Singularity 6, Bossa Studios, PnkFrg, Treehouse Games, and many others.

Our investment Criteria:

• The company must be related to the gaming ecosystem e.g. at least one segment of their business focused on gaming

• Stage: Pre-seed or Seed

• Investment terms: We will invest anywhere between £250k to £2m for a 10% – 20% equity stake

• What we typically invest in: interactive entertainment, studios, content, technology, platforms, and services related to the gaming/interactive entertainment industry.

Our Value Add:

All the partners are ex-operators within the gaming industry. This means we’ve done 2-founders-in-a-garage start-ups. We’ve helped companies transition from a back-of-an-envelope vision to a multi-billion-dollar powerhouse. Our passion is to help our founders strategically, financially and operationally. We speak the same language, share the same references, understand the same challenges and will bring real experience and deep understanding.

We like to give our founders an unfair advantage. We will leverage our network, reputation and far-reaching connections in the gaming industry to support our portfolio companies across all stages. We’ve helped our portfolio companies recruit for key positions, define their product strategies, formulate company culture, given executive coaching and assisted in raising multi-million-pound follow-on funding rounds with one of the best in-class graduation rates in the industry.

Deck submissions.
At Longwall Ventures we invest in early-stage businesses that are harnessing the UK’s longstanding research and development expertise to address the global challenges of tomorrow in the health, resilience and sustainability sectors.

We invest in companies with strong IP that have the potential to either disrupt an existing market or gain a large share in a new one. Our portfolio is diverse; ranging from space antennae to life science tools, controlled environment agriculture to solar panels. We are interested in B2B businesses developing hardware or wetware solutions to societal challenges and have relevant scientific and commercial experience which means that we understand what it takes for these companies to succeed. We like to invest when a technology has been proven in a laboratory environment and work with the team on commercialisation and growth. We have a long track record of investing in deeptech companies and building high-growth ventures.

Our typical first investment can be ~£500k-£1.5m and we are often the first institutional investor in a company. The typical holding period for our investments can be 10 years and we aim to be an active part of building the business over this time. Our investment managers have extensive experience from pre-start-up through to exit, supporting teams with strategy, recruitment, fundraising, go-to-market, exporting, strategic partnerships and so much more along the way.
Low Carbon Innovation Fund 2 (LCIF2) is a seed stage investor in low carbon technology businesses based in or operating in England.

The fund’s investment size is up to £450k per round and LCIF2 co-invests with other private sector investors on all transactions.

The fund is managed by Turquoise International.

Low Carbon Innovation Fund
Turquoise International Ltd
Turquoise.eu

Contact:
Fund fully committed – we are not seeking new investment connections at this stage.
Maven is one of the UK’s most active SME investors, with around 100 executives based across our network of regional offices. We partner with ambitious, dynamic, entrepreneurial management teams headquartered anywhere in the UK, at any stage of their life cycle and across a wide range of sectors to provide essential capital and expertise to unlock potential, drive innovation and help accelerate growth.

Our values:

- We believe that the most effective way to build strong relationships with management teams is to operate at a local level. That is why we have expanded our regional network of offices to ensure our executives are located across a number of the UK’s key economic hubs.

- We build lasting relationships based on trust and respect through being an effective and active investor without diluting the ability of the management team to run the business.

- We look to invest responsibly, including backing businesses that are making a real impact on addressing environmental, social and governance issues facing society today. We see supporting the enhancement of ESG credentials as a positive step change that helps deliver long term, responsible and sustainable growth in our portfolio companies.

Maven became a signatory to the internationally recognised Principles for Responsible Investment in June 2021.

- Maven is a signatory to the Investing in Women Code, a commitment to support the advancement of female entrepreneurship in the UK, in which we are dedicated to improving their access to tools, resources, and finance.

- Our core investment objective is to help deliver growth and maximise shareholder value. Our capital brings secondary benefits to the wider economy, helping to secure thousands of British jobs whilst also stimulating further job creation as each business grows.

In working with Innovate UK as an Investor Partner, Maven is excited to partner with dynamic companies to drive growth and build on our rich heritage of supporting innovation and R&D.
M Ventures is a strategic, corporate venture capital fund, with a mandate to invest in innovative technologies and products with the potential to significantly impact the business priorities of Merck.

From its headquarters in Amsterdam and offices in Germany, US and Israel, M Ventures invests globally in transformational ideas driven by great entrepreneurs in line with its two investment areas Biotechnology and Technology. M Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. While M Ventures is formally separated from Merck by a strict firewall policy, our portfolio companies benefit from our deep experience in building and growing early-stage companies and from our access to Merck’s expertise and network.

Contact:
sarah.luppino@m-ventures.com

M Ventures
m-ventures.com
Mercia Ventures one of the UK’s most active venture capital investors. From early-stage to scaleup investment, our investment team operates from a shared set of beliefs, partnering with entrepreneurs for the long term.

We offer venture capital investment from £1 million up to £10 million and support our portfolio companies at every stage of their growth. Mercia Ventures is an ideal partner for sourcing, supporting and investing in the UK’s most promising businesses. Our strong track record, unparalleled network and commitment to growth make us a leading choice for founders looking for investment that goes beyond capital.
Minerva Business Angels is a brand name of the University of Warwick Science Park Ltd [“UWSP”], a wholly owned subsidiary of the University of Warwick.

Beauhurst has accredited Minerva Business Angels as the 2nd most active angel network in the UK and the most prolific investors in the Midlands on a deal basis. The Scaleup Institute identified Minerva as the UK’s second most active green scaleup economy investor.

Minerva operates to a not-for-profit objective and seeks to help fill the gap between the £0 - £3m turnover. Our membership includes investors, family offices and venture capitalists.

UWSP formed the predecessor to Minerva in 1994 to support its Tenants seeking investment. In 2010 UWSP formed Minerva (a brand name of UWSP), whose members have invested in over 100 companies and around £20mn, with an estimated leveraged figure of around £60mn in co-investment.

Minerva delivers its services, matching investors with founders through a collective of universities. Universities have a “beacon effect” to attract members, and we run a face-to-face offering (to co-located investor groups) through Aston, Birmingham, Loughborough, Nottingham, and Nottingham Trent. Furthermore, Minerva operates a face-to-face meeting for investors located around Warwick, Leamington Spa, Cheltenham and London through Warwick Business School.

We deliver Minerva Birmingham PitchUp, which is a joint effort between Aston Birmingham and ourselves. Minerva Birmingham Pitch Up supports companies from all over the Midlands, who are invited to apply, receive investor training, and are subject to panel reviews from experts. Those selected enter the PitchUp competition run together with West Midlands Venturefest. Further to the face-to-face model, we also deliver webinar pitches to accommodate those who can’t make the above groups and provide an ongoing educational series to our investors and companies.

In all, Minerva facilitates the connections between investors and founders but given its non-regulated status, doesn’t get involved in the deals or negotiations.

All applicants are subjected to a due diligence process to ensure they fit our investors’ interests and are interviewed for capability assessment. When a further review is deemed necessary, they are put out to our experts in the investor community. This provides for a deal pipeline in excess of 400 companies, the majority of which are Tech related businesses.

Of those applying, 70-80/year are invited to pitch, the majority of which are within net zero, health & well-being and next-generation digital technologies and technology.
MMC Ventures is one of the most active early-stage tech investors in Europe, focused on Series A. During the past two decades, we’ve built a successful track record of supporting high-growth technology companies. We distinguish ourselves through our commitment of going deeper – on the technologies we invest in, and the partnerships we build with founders.

We conduct in-house research, providing us with a differentiated understanding of emerging technologies and sector dynamics to identify the areas and themes that have the potential to create the next multi-billion European success stories. Our portfolio spans enterprise AI, fintech, data-driven health, cloud and data infrastructure, with notable investments such as Snowplow, Copper, YuLife, Peak AI, Synthesia, Recycleye, MindsDB, Ably and Signal AI.

If you’re a tech founder looking to raise at Seed or Series A, we would love to hear from you. You can visit our website for contact details and more information.
Nesta is the UK’s innovation agency for social good.

Nesta has set 3 impact goals for 2030 which reflect Innovate UK’s Future Economy priorities:

• Accelerate the decarbonisation of UK household activities and increase productivity through increasing green skills
• Increase the number of healthy years lived through tackling obesity and loneliness
• Narrow the outcome gap between children growing up in disadvantage and the average, with a focus on pre-school years.

Nesta Impact Investments backs tech ventures that can contribute to Nesta’s impact goals, delivering both a social/environmental and financial return. As such, we invest in: edtech, foodtech, healthtech and sustainability. We typically invest at Seed stage to Series A, £500K-£1M initially with capacity to follow on.

Nesta has set up Mission Studio in partnership with Founders Factory through which we initiate startup ventures and attract founders who want to build successful commercial businesses that deliver on our impact goals.

Nesta’s broader team includes expertise in data science, user design and technology, and through its recent integration of the Behaviour Insights Team (BIT) world leading behavioural science expertise. We look to draw on this broader suite of resources, working in collaboration with founders, to accelerate the success of ventures we back. For founders building businesses in relevant markets, drawing on Nesta’s networks, domain expertise and technical skills is a real advantage.

If you are a founder looking to apply for investment at Seed to Series A please visit nestainvestments.org.uk or contact investing@nesta.org.uk

You can find more information at nesto.org.uk/project/mission-studio/
NoBa Capital are actively building a portfolio of early stage tech-enabled businesses that are shaping the future of work.

We invest at pre-seed and seed stages (generally £100k to £1.5m) and actively support and collaborate with the portfolio to achieve successful growth. We believe the building amazing businesses is about the idea, the people and great execution – which is why we actively help our portfolio with capability build and delivery.

Together with our portfolio companies, we are on a mission to positively impact the lives of 10 million workers by 2028. We firmly believe that the best opportunities are businesses that deliver work-centric solutions, whether through access to work opportunities, career development, diversity and inclusion, financial stability, wellbeing, or flexibility.

If your business is building an innovate solution to support workers in the future of work please reach out to connect.

Pitch Deck Submission.
The Northern Angel Hub is led by the North East Business and Innovation Centre in partnership with the Innovation SuperNetwork, NorthInvest, Fund Her North and the UK Business Angels Association. We connect innovative technology ventures to investors and manage the investors’ deal flow, investor readiness activities, facilitate introductions to investors and undertake commercial due diligence.

We help companies based in the North East, Yorkshire & Humber, North West and East Midlands. We have an investment focus in innovation and technology with expertise in Health Tech and Life Sciences, Digital and Technologies, Clean Growth and Advanced Manufacturing. Our ambition is to plug the geographical and gender funding gap and accelerate sustainable and inclusive investment in innovation in the North.

We support companies at pre-proof of concept stage through to Series A, with ticket sizes of £150k to £3m. We represent a network of over 350 investment organisations, 25,000 investors, over 250 innovation support organisations such as universities and Catapults and we have supported over 3,500 technology and high growth companies. The consortium has an angel network of over 200 regional angel investors. The Northern Angel Hub leverages this network to grow innovative early stage businesses. We have a strong track record of supporting innovative start ups through the fundraising process and across all types of funding mechanisms with a particular focus on equity and grants.

Since the Northern Angel Hub launched in 2019, we have helped 77 businesses with a mix of grant and seed funding totalling £39m. 38% of these businesses supported have been founded by diverse entrepreneurs.

Companies and entrepreneurs working with us are able to access the support provided by the organisations powering the Northern Angel Hub. For example, the Innovation SuperNetwork runs the Accelerating Investment and Innovation Summit, VentureFest North East and the Newcastle Angel Hub. It provides expert project management, undertakes independent due diligence and assessment of applicant businesses and provides support to companies developing grant applications and fundraising. NorthInvest champions northern innovative technology and fuels the early stage economy by providing connections to early-stage funding at a critical point in the life cycle of Northern tech start-up businesses. In October 2020 NorthInvest launched Fund Her North, an initiative to improve access to funding for female-led businesses in the North of England through start-up, scale up and exit. Fund Her North also operates a women angels network.
Northern Gritstone is an independent business that helps amazing people who are living and working in the North of England to create the world-class businesses of tomorrow based on the world-class science and innovation that exists in the North of England today.

Northern Gritstone aims to support the commercialisation of science and IP-rich businesses based in the North of England – many originating from our partners at the Universities of Leeds, Manchester and Sheffield. Many of these opportunities are in the UK’s most exciting emerging sectors such as advanced materials, health technology, cognitive computation and artificial intelligence.

Northern Gritstone was founded with the philosophy of Profit with Purpose, combining attractive returns for shareholders with wider positive, societal and economic impact, including supporting Levelling Up and high-skilled job creation in the North of England.
Northstar Ventures is an FCA-approved VC fund manager based in Newcastle. Since 2004 we have supported early stage technology companies with pre-Seed to Series A investments across many technology sectors and market verticals.

Typically, we invest from £50k to £250k initially with multiple follow-on investments, based on delivery of milestones. Investments are in the form of minority equity stakes, quasi equity and occasionally loans. We seek co-investors wherever possible to build supportive syndicates for each investee company.

Our funds are focused on supporting businesses based in the North East and delivering impact locally. We have built a highly experienced team of investment professionals and are one of the UK’s leading regional VCs.

We are building on this platform with an ambitious strategy focusing on investments into companies addressing complex social and environmental problems at scale (‘society tech’). Within this we see enormous opportunities for innovation and value creation, particular in Net Zero, Healthy Ageing and Digital Solutions. We already have a number of portfolio companies who are active in these areas.

Crucially, we are raising a new fund, Venture North, which will be dedicated to investing in society tech. This new fund will focus on university spin-outs and ‘spin-ins’ i.e. companies working closely with universities and other research institutions sharing IP/ttech/resources.

The SMEs that we will support via this programme must be undertaking innovative R&D projects, comprising feasibility studies, industrial research or experimental development. Projects must focus on one or more of the specific themes outlined in the Innovate UK Plan for Action, including Net Zero, Healthy Living & Agriculture, Digital & Technologies.

Grants sizes, intervention rates and project lengths depend on the research category. We will match grants with investment from our funds under management and from our wide network of co-investment partners.

Adding value to the portfolio:
We understand that the best investors provide considerably more than capital alone. All our team have experience of supporting multiple early stage technology businesses and wide experience and knowledge of the typical challenges that such companies face. We also have a wide network of advisors and NXDs whom we routinely introduce to our investees. We often introduce investees to other trusted service providers such as marketing agencies, recruiters, lawyers, corporate finance and other professional services, depending on needs. We have excellent networks with the innovation ecosystem including universities, technology parks and Catapults.
o2h Ventures is an established fund manager based in the heart of the biotech community in Cambridge, UK. o2h Ventures Limited is authorised by the Financial Conduct Authority (FRN 812245). We are a specialist fund that invests in biotech therapeutics and the intersection between biotechnology and AI/ML. o2h Ventures was launched in 2018 to provide pre-seed and seed capital to Great British biotech innovations. To date the fund and pre-fund has invested into over 28 biotech therapeutic companies of which two have clinical proof of concept data, and one has listed on the public markets.

o2h Ventures has two specialist tax efficient funds open for investment on a 6 monthly basis - The o2h human health SEIS Fund and The o2h human health EIS knowledge-intensive Fund

The focus of o2h Ventures is to seek out biotech therapeutic opportunities within the UK and then support these ventures through investment and connections into the pharmaceutical industry. Our aim has been to find exciting early-stage opportunities that can be nurtured in the UK biotech ecosystem and thus build a pipeline of innovative medicines and investment opportunities for later stage funds and pharmaceutical companies to invest into or acquire. We have focused on de-risking the investments by understanding areas of high interest to big pharma and then providing ‘hands-on’ support via team building, mentoring, fundraising, scientific support and seeking commercial partnerships.

Interested investors or companies that would like to be considered for funding can contact us at invest@o2h.com.
Octopus Ventures is one of the largest and most active venture capital investors in the UK and Europe, investing in and supporting the people, ideas and industries that are changing the world.

We’ve built expertise across seven sectors: B2B software, climate tech, consumer tech, deep tech, fintech and health and techbio. We’ve backed more than 180 businesses across the UK and Europe, including successes like Zoopla, WaveOptics, Evi and Orbex. We invest in people and teams from as early as ideas on a page all the way through to the later stages of growth, providing capital, expertise, and partnership.

We manage £2bn for our retail and institutional investors and invest £200m each year. We’re part of Octopus Group, a group of entrepreneurial businesses united by a common goal: backing the people, ideas and industries that will change the world.
Old College Capital (OCC) is the University of Edinburgh’s venture investment fund. OCC manages Edinburgh’s early-stage investment activities and shareholdings, supporting exciting ideas and technologies emerging from the University. Working with our founders, investors, and the ecosystem, OCC accelerates the journey of startups and spinouts looking to make a positive impact on people and our planet.

We invest in deep-tech, high growth companies associated with the University from pre-Seed to Series A, typically writing cheques of between £50k and £250k. Our team are early-stage specialists, passionate about getting ideas from our staff, students, and research out into the world to make a difference. We are active and engaged shareholders but invest with a long-term patient capital approach. We continue to support post-investment including joining boards as observers, leveraging the expertise and network of the University and by following our money in subsequent rounds.

We recognise different investors bring varying perspectives, experiences and expertise and we look to help Edinburgh companies find the right investors for them. We follow a co-investment model, working collaboratively with a wide range of investment partners. Collectively, OCC and its partners invested over £100m in University of Edinburgh associated companies last year.

Old College Capital
oldcollegecapital.com

Contact:
investment@ed.ac.uk
OnePlanetCapital invests into businesses tackling climate change and the world’s biggest environmental problems.

As you can see from the portfolio page on our website (https://www.oneplanet.capital/portfolio) we have invested in a wide and diverse range of UK businesses all unified by the fact that they tackle in one way or another climate change or environmental problems.

We typically invest circa £500K - £1M into high growth, early-stage but post revenue businesses based in the UK. On occasion we can invest into pre-revenue businesses providing we can evidence that the business will generate revenue within a short and acceptable time frame following investment.

An investment by OnePlanetCapital into your business means a whole lot more than just receiving money. We provide our portfolio companies with the support, help and mentoring that every entrepreneur needs in order to turn their dream into a success.

Why should you choose OnePlanetCapital over another fund?

As proven and successful entrepreneurs, the OnePlanetCapital team have the knowledge, skills and experience to help you grow your business, whether that’s new ideas, talent or just a sounding board.

To apply for funding please visit: www.oneplanet.capital/entrepreneur-application
Oxford Science Enterprises (OSE) is an independent, billion-pound investment company, created in 2015 to found, fund and build transformational businesses via its unique partnership with the University of Oxford, the world’s #1 research university.

This partnership enables OSE to work with the brightest academic minds tackling the world’s toughest challenges and guarantees unrivalled access to their scientific research. In collaboration with its global network of entrepreneurs and advisers, OSE goes well beyond funding to shape and nurture these complex ideas into successful businesses. Actively focused on a core portfolio of around 40 companies spanning three high-growth, high-impact sectors – Life Sciences, Health Tech, and Deep Tech – the company adopts a flexible, long-term investment approach, recognising the path from ground-breaking research to global markets takes time and resilience. To date, OSE has invested £0.6 billion in over 80 ambitious companies built on Oxford science.

Oxford Science Enterprises invests in spinouts from Oxford University, the Science Parks and Said Business School, so this contact is only suitable for companies where there is a strong Oxford link.

Contact:
ideas@oxfordsciences.com
We invest in science and technology companies from start-up. We start our investments under the SEIS scheme. We are looking for companies for whom a relatively small investment, possibly supported by an Innovate grant can lead to a transformation in value. A first experiment, prototype, market interaction can be a place to start.

We have a lot of experience (~ 60 years) in helping companies get their innovations proven developed and to market. It is difficult to predict where our input might come in. It might be contacts, strategic, adjacent technologies, help with paperwork, finding a first customer, some fundraising. Please take a look at our quarterly report to see the variety of companies we invest in.

Oxford Technology
oxfordtechnology.com

Contact:
Otseis@oxfordtechnology.com
An active, hands-on investor, capable of taking the lead position on Seed to Series A investment rounds. Based in Edinburgh, we focus on companies located in Scotland, Northern Ireland and the North of England.

We can often participate in, and sometimes lead, follow-on investment rounds, meaning that we offer long term financial backing alongside our wider strategic support of businesses. We have a successful track record of taking early-stage tech companies from idea to exit and being held up as regional or global leaders in their respective categories.

What you can expect from Par Equity:

- When we invest, we make a commitment to accelerate your business through the guidance, support, and trust of the Par Equity team and our extensive network of industry-professionals
- We understand the challenges that B2B tech companies face in procurement processes, sales cycles, and tech integration and we are experienced in helping companies with firmware and hardware componentry. We have a strong track record supporting our portfolio to overcome these hurdles among others
- We always seek to appoint a Par Investor Director and Observer to your company’s board, providing guidance and counsel to your management team and bringing strategic thinking to the business
- We have access to new talent and relationships as and when your business needs it, fuelled by our extensive network of head-hunters, recruiters, regional chairs, and universities
- We take an active role in your follow-on funding needs. We will work with you to find new investors, and we regularly follow our money to support our portfolio companies
- We care about ESG and, as steering committee members of ESG_VC, we encourage active discussions on ESG specific to your company, annually reviewing your progress and helping to set objectives
- We support our portfolio companies with market expansion, most recently helping TriVirum grow their US presence
- We hold annual events across the entire Par Equity ecosystem, allowing portfolio companies to create valuable relationships that drive business forward

What We Look For

- Based in the North of the UK
- B2B focused
- IP driven / Applied Deep Tech
- Seed to Series A
- £0.5m to £10m total raise
- We’re seeking proven commercial demand, with monthly revenues of more than £20k

In line with our ESG investment policy, we will not invest in companies that:

- Encourage the consumption of tobacco, alcohol and gambling
- Are directly involved in animal testing
- Are selling technology for applications in weaponry
PDS Limited is a US$2bn+ global enterprise and one of the largest organisations in Asia dedicated to the design, product development, sourcing, virtual manufacturing, and distribution of consumer goods. PDS operates from a global network of 50+ offices in 22 countries across Europe, North America, Middle East, and Asia.

Instead of remaining as an apparel sourcing company, PDS today is a platform business that has evolved into being one of the most favoured designer-manufacturer for some of the world’s leading brands and retailers with a strong customer base of 200+ companies part of FTSE 100, S&P500 and DAX30. Capitalising on recent market trends, PDS has also developed several in-house proprietary brands, undertaken collaborations with celebrities and influencers, along with licensing or acquiring brands.

PDS Ventures is the investment and innovation vertical of PDS Group and is a forward-thinking venture capital arm that strives to marry sustainability and technology innovation with an aim to build an ecosystem where all the companies can grow and thrive together.

**Investment criteria:**
- Sector focus: Sustainability (materials innovation, circular economy, manufacturing solutions, sustainable communities), Digital first consumer brands tech (investments in brands focussing on consumer sectors), Technology (AI, fashion tech, retail tech, consumer and wider enabling technology)
- Stage: Pre-Seed to Series A

**Value add:**
- Entrepreneurial-led early-stage venture, spin-out from universities, university projects, seeking first/second round of fundraise
- A founding team of at least 2 people with relevant technical experience and business acumen, with a commitment to diversity and inclusion
- Market with high-growth potential and clear exit pathways
- Demonstrated interest from major brands and manufacturers as customers, R&D pilots and/or investors
- Clear sustainability credentials, with measurable impact

*PDS Ventures*

pds ltd.com/pds-platform/pds-ventures

**Contact:**

pdsventures@pdsltd.com

- Active business development support and introduction to 200+ leading brands and retailer customers (PDS customers)
- Active support setting up supply chain through partnerships with more than 700 factories globally
- Active fundraising support
- Potential integration into the PDS supply chain or into the PDS ecosystem (depending on scale and stage of company)
Pioneering Ventures provides equity funding to early-stage life science companies. We invest in founders with vision and ambition alongside game-changing technology. We prefer to be the first investor and will often follow our investment in subsequent rounds, but we are happy to co-invest and bring in co-investors.

Our venture building and investment team will help you develop and refine your business proposition and support the growth of your business in the challenging early years. You will also have access to the nationwide Pioneer Group network of some of the leading experts in their field. We use this to help you fill key roles such as Chair or SAB.
Praesidium is a London-based Agri-FoodTech fund, investing in early to mid-stage companies in the Agricultural and Food Technology sectors within the UK, Europe, Israel and North America. Praesidium invests directly into companies, partnering with ambitious and visionary entrepreneurs and founders to address the challenges which the agricultural and food industries are faced with.

While we invest along the entire value chain, our focus areas for investment include:

**Reinventing Farming:** Enhancing existing farming, making it more efficient and reducing the stress it puts on resources using break-through technologies like AI, IOT, sensors and monitoring. New ways of reinventing the idea of farming such as sustainable aquaculture, innovative animal feed, novel crops and technologies allowing new farming systems.

**Clean Food:** Producing food without increasing the pressure on resources and the environment through the application of novel technologies which allow to “grow” sustainable, traceable and nutritious food ingredients and novel foods.

**Alternative Protein Sources:** Providing enough protein for the increasing world population as a replacement or an alternative to meat, dairy and other products.

**Functional & Personalized Nutrition:** Using data and new technologies to provide functional ingredients and foods to address specific health concerns and lifestyle diseases (e.g. gut health) and to develop optimized personal nutrition.

We are specifically seeking companies with a B2B technology, supported by defensible IP and company know-how. Our focus lies on investments in earlier phases (specifically Late-Seed, A and B financing rounds), where we can leverage our global network and expertise to help commercialise and scale up technologies. We will also consider funding companies at a more advanced stage, where we can support accelerated growth through the power of our network.

Praesidium S.A.
praesidium.eu/praesidium-agri-foodtech/

Contact:
dalton.tice@praesidium.eu
Praetura Ventures is a Manchester-headquartered VC that backs exceptional early-stage businesses and founders across tech and life sciences with More Than Money.

Praetura's More Than Money offering ranges from significant business cost savings through the VC's industry-leading Portfolio Toolkit, to support and mentorship from business heavyweights.

The latter is delivered through Praetura's Operational Partner Programme, which connects founders with highly talented, C-suite level professionals who have helped scale brands like Dr Martens, AO.com, MPP Global, OSTC – and previously Apple and ANS.

Praetura currently has over 33 companies in its EIS portfolio, including a number of regional success stories such as Peak AI, XR Games, Culture Shift, BankiFi, LCC and Modern Milkman.

What separates Praetura from other investors is a focus on the North of England, with two-thirds of Praetura's portfolio based in the North.

The VC also manages an early-stage healthcare fund with Greater Manchester Combined Authority, Cheshire and Warrington LEP and Bruntwood SciTech.

Furthermore, Praetura is the largest delivery partner on British Business Investments’ Regional Angels programme. This highlights the VC's ongoing commitment to the North – a region which receives only 7% of UK-wide VC investment, leaving a £9.7bn shortfall, as evidenced in Praetura's white paper ‘What’s Powering The Powerhouse?’.

The North aside, Praetura is committed to clear, transparent and informative communication with founders, investors and its growing network of advisers, helping Praetura to achieve its mission of being the VC of choice for early-stage founders looking for more than an investor.
Mission driven investor seeking opportunities to invest in oncology focused companies with the potential to focus on prostate cancer.

Prostate Cancer Research tailored approach, collaborative ethos and focus on patient impact supports patient-centric product development to ensure new technologies reach the clinic sooner. Our investment strategy goes beyond the purely financial, providing scientific, clinical & commercial insights.

Prostate Cancer Research (PCR) has over thirty-year’s experience of funding impactful biomedical research in prostate cancer. Our funding in research such as radiotherapy, immunotherapy and AI are driven by our deep understanding of patient need. In 2021 PCR launched its translational programme, Proven Connect, to harness the charities expertise and networks in supporting promising innovations from academia through to Series A.

Proven Connect accelerates the translation and uptake of innovations in therapeutics, diagnostics, medical devices/Medtech and AI/data driven solutions. Our programme is supported by individuals who have extensive executive experience in developing startup and mid-size Pharma/Biotech, a deep knowledge of urological cancers and specialist clinical care, Pharma, healthcare regulation and patient advocacy.

If you are interested in learning more about how Proven Connect can support your company to succeed, please email Sonja Lawrence at Slawrence@pcr.org.uk
QantX are dedicated investor partners committed to fostering exceptional talent, bold innovation, and transformative solutions born in the Greater South West. We’re particularly excited by helping to accelerate highly impactful innovations tackling crucial global challenges in Sustainability and Healthcare from the early Pre-seed stage through to Series A.

We’re seasoned entrepreneurs and operators. We understand the grind, the passion, and the thrill that comes with launching and scaling a start-up. We provide not only funding but also strategic commercial guidance, c-suite level global connections, and specialized sectoral insights with the support of our diverse and ever-expanding advisory group.

Let’s embark on this journey together. For more information, feel free to drop by our website at www.qantx.co.uk. Alternatively, you can reach out directly to us at enquiries@qantx.co.uk. We’re always ready to chat and explore how we can help.
QUBIS is the technology transfer and investment arm of Queen’s University. It has a track-record of over four decades in creating disruptive start-ups, helping commercialise cutting-edge technology from the University’s research-base, and generating investor returns from deep tech-based companies. Notable successes include: Kainos, Andor Technology and Fusion Antibodies, all of which have been listed on the London Stock Exchange. As the most active private seed investor in Northern Ireland, 75% of the top-funded deep tech startups in the region in the last five years have originated from QUBIS.

Our investment focus and expertise are in University Spinouts, and Spin-ins. We also manage and heavily participate in the InnovateUK-funded ICURe programme, which we use to focus on the best opportunities emerging from the UK University sector.

Our website www.qubis.co.uk provides an overview of our team of investment professionals, and the current portfolio of investee companies, together with contact information. For further details please contact CEO, Brian McCaul via email: info@qubis.co.uk

We typically lead pre-seed rounds using either straight equity or CLNs and invest either alone or alongside other institutional investors and/or angel investors. We typically follow our money through subsequent investment rounds.

We have developed expertise in building early-stage teams, in structuring share cap tables to reflect both the inventive steps which created valuable IP, and to incentivise those entrepreneurs who are in the business full-time driving growth and value. Our team of investment professionals have experience of working with companies from pre-incorporation through to IPO and beyond and will bring those skills and experience to new investment propositions.

Our investments to date, reflect the research base of Queen’s University, Belfast. We have a burgeoning life science portfolio ranging from therapeutics, through vaccines to diagnostics, a NetZero grouping with carbon capture technology and efuel expertise and a growing software grouping with AI, cyber and digital transformation.
As part of Rabo Investments, Rabo F&A Innovation Fund invests early growth capital in innovative companies across the Food & Agri (F&A) supply chains with a geographic focus on Western Europe, Israel and the North America.

As proactive investors, we are dedicated to fulfilling a supporting role and building value by leveraging Rabobank’s F&A network, knowledge and position for the benefit of the companies in which we invest.

Rabo Investments
aboinvestments.com

Contact:
bar.rubin@rabobank.com
Regenerate Ventures invests in early-stage agricultural innovation that has a positive impact on the health of our planet, society and future climate.

Regenerate Ventures is an AgTech fund investing in early-stage agricultural technologies that are helping farmers to transition to more sustainable farming practices and to decarbonise the agricultural sector. We look for seed and growth stage start-ups. We make sure the companies have a minimum viable product that is ready for market and globally scalable with multi-billion-dollar opportunities. We focus on upstream AgTech (inside the farmgate) in areas such as bioTech & genetics, robotics, AI, data science, satellite imagery and sensors.

Regenerate Ventures invests smart patient capital into early stage AgTech companies and uses their expertise and understanding of the agricultural sector to help these companies test and trial and then commercialise their technologies. They have a deep understanding of how the agricultural sector works and a large network within it from research centres through to the major corporates in the industry.

The Regenerate Ventures team and advisory board have over 200+ years of combined experience in the Agricultural sector as well as having deployed 4 private equity funds and 2 venture capital funds. They have put over £500m to work across Agriculture, climate and renewable energy projects over the last 20 years.
Sainsbury’s has committed to investing £1 billion towards becoming a net zero business by 2035. While 70% of this target can be achieved using existing solutions, a 30% gap remains where new technologies and solutions need to be identified, tested and deployed.

Sainsbury’s Innovation Investments (S2I) – working with WAE – embraces the need for these groundbreaking net zero technologies.

Sainsbury’s Innovation Investments will invest in early-stage companies who are developing new and disruptive technologies that can support Sainsbury’s net zero goals.

We will look to deploy at least £5m over 4 years with initial investments up to £500k with potential to expand further. The retailer can lead or coinvest alongside other investors.

As part of the investment Sainsbury’s will trial the technologies within its operations with potential for wider estate roll-out across its 1,500 national sites.

Companies will also benefit from WAE’s investment experience receiving technology development, product, manufacturing & supply chain guidance, and introductions to WAE’s partners and co-investors.

Investment Criteria:

- European headquartered companies or companies with a European base
- Technologies that have the potential to be deployed across Sainsbury’s operations
- Post “proof of concept” stage
- Pre or post-revenue
- Pre-seed, Seed or Series A stage

Contact:
ventures@wae.com
SCVC is a Bristol-based venture capital firm offering investment into early-stage UK deep tech companies, focusing on technologies that have the potential to improve healthcare, quality of life, and the environment around us.

SCVC was founded to back exceptional teams building game changing UK-based deep tech companies with investment and qualified mentorship. We get excited by truly standout technology that has the potential to disrupt existing industries or create entirely new ones, and we love investing at the early stages of a company's journey.

We’re a team of serial entrepreneurs, investors and scientists who have unique insight into the challenges facing young deep tech companies and we’re supported and backed by successful entrepreneurs behind multiple tech and deep tech exits in the South-West. We bring a hands-on, tailored approach to supporting and mentoring our portfolio companies, focusing on setting them on the best path for growth and success from the outset.

SCVC is part of the Science Creates ecosystem, with two incubators in Bristol, offering over 45,000 sqft of purpose-built laboratory space, flexible offices and event space, alongside the support of a network of academic institutions, strategic delivery partners, advisors and mentors.

We focus on three main things: truly disruptive technologies; solving the world’s greatest challenges, such as revolutionising healthcare and the climate crisis; and founders with ambition, drive and resilience. We’re particularly interested in backing founders who are driving discoveries made through the convergence of multiple advanced technologies like AI/ML, engineering biology, quantum and photonics, and advanced materials.

Why Choose SCVC?
Partnering with SCVC means you get support from a team that has first-hand experience of how to successfully go from company founding to exit and the challenges that need to be navigated along the way, particularly those unique to deep tech companies.

We will actively lead investment rounds and ensure you secure the capital necessary to make meaningful progress and help unlock further investment rounds when needed. We also believe that investment is only one of the key ingredients needed for success — deep tech companies also need specialist support to really thrive. We provide hands-on support, mentorship and sector expertise and, as part of the Science Creates ecosystem, we can connect you with a network of entrepreneurs and professional service providers who can advise on everything from business strategy to legal and tax advice.
SETsquared is the enterprise partnership of the Universities of Bath, Bristol, Cardiff, Exeter, Southampton, and Surrey. We provide a range of specialist business, investment, and innovation support programmes and, since 2002, have supported over 6,000 companies to raise £3.9bn investment.

Our programmes are designed to support ventures across their lifecycle from idea to start-up and spin-out to scale-up and growth. They are tailored to high-tech, high-growth ventures focusing on AI & advanced computing, quantum tech, health tech, advanced materials, environmental tech, and robotics.

SETsquared provides significant additional services to investee SMEs through our range of programmes tailored to the different stages of company development. Our programmes provide a comprehensive suite of support to high-tech companies, including business reviews, incubation, mentoring, access to professional services, support in accessing public R&D funding, investor readiness training and access to specialist networks. Further, we provide access to the extensive expertise, knowledge and facilities of our six research-intensive universities with over 100,000 students and delivering upwards of £600m pa of Government funded research across all Innovate UK Future Economy themes and technology families plus access to graduates, interns, placements and collaborative R&D projects.

We partner with many leading angel groups which invest across all sectors. Examples include Angels Invest Wales, the designated angel investment body for Wales, building and facilitating new angel syndicates, plus an £8m co-investment fund through the Development Bank of Wales; Bristol Private Equity Club, a growing angel syndicate spanning the Bristol area, with a strong track record in backing innovative high-tech businesses; Science Angels Syndicate with over 50 members supporting businesses across the UK with a focus on S/EIS eligible businesses with ambitions to impact society on a large-scale in sectors including Life Sciences, Advanced Materials, MedTech and Digital Health.

The overall deal capacity of our angel groups and their 1000 members in 2021/22 was 50 deals ranging in value from £50k - £1.5M. Our partner syndicates represent a particularly strong grouping with equity investment capacity estimated at £15m pa with additional co-investment opportunities alongside their deals. Through SETsquared’s Regional Angel Investment Accelerator, 19 companies were supported to win £3.3m in funding leveraging over £8.6m in investment.
SFC Capital is the UK pre-seed specialist and the most active venture fund in the UK. We invest in the innovations of tomorrow and the companies that will shape the Future Economy from their very first funding round.

Investment criteria: companies must be SEIS eligible (raising their first funding round) and developing a proprietary innovation that has significant commercial potential. Our core sectors of interest are B2B Software, Life Science & Medtech, Green Technology, IoT and Consumer Technology. But as a generalist fund, we are open to consider opportunities across any sectors.

We lead pre-seed funding rounds alongside angel investors and early-stage funds to provide the all-important seed capital allowing innovative companies to take off on their journey.

SFC Capital Ltd
sfccapital.com/register/startup

Contact:
info@sfccapital.com

We support companies across fundraising, financial management, commercial, hiring etc. from the earliest stages through to a successful exit.
At Social Tech Trust (STT) our vision is a world where social transformation is the driving force behind tech. We’ve played a vital role in developing the social tech ecosystem and have built an extensive track record of successfully supporting ventures to deliver financial and social returns.

Since 2008, we have directly supported over 300 ventures, providing more than £30m of funding, with over 30 million people benefiting from our ventures’ products and services.

We invest in impact driven tech companies at seed stage and series A. We aim to provide ambitious founders with the aligned investment they need to scale profitable and sustainable companies. To do this, we invest using a flexible VC approach, which is a hybrid between revenue-based investment and established equity-focused VC models.

Within our investment criteria we specifically target companies that:

• Focus on growing revenues and profitability
• Have a social mission (linked to strategic areas including health inequalities, financial and economic resilience, climate justice)
• Advance equality for underserved groups through their tech products/services

We add value to our portfolio companies in 3 main ways:

• Strengthening revenues through our networks and connections to public, private and public sector partners/customers
• Building capacity in key areas including tech, impact management and equality, diversity and inclusion (EDI) by providing access to a curated network of specialist service providers and advisors
• Driving collaborative advantage by providing access to our peer-to-peer community

With over a decade of experience, we know tech has the potential to play a crucial role in addressing some of the greatest social challenges we face today.

Social Tech Trust
socialtechtrust.org

Contact:
hello@socialtechtrust.org

We add value to our portfolio companies in 3 main ways:

• Strengthening revenues through our networks and connections to public, private and public sector partners/customers
• Building capacity in key areas including tech, impact management and equality, diversity and inclusion (EDI) by providing access to a curated network of specialist service providers and advisors
• Driving collaborative advantage by providing access to our peer-to-peer community

With over a decade of experience, we know tech has the potential to play a crucial role in addressing some of the greatest social challenges we face today.
With more than $1.6 billion in assets under management and more than 300 investments per year, including 100+ pre-seed rounds in new startups, SOSV is one of the most active venture investors in the world. Our industry-leading startup development programs include HAX (hard tech) and IndieBio (biotech).

SOSV’s core mission is to fund visionary, deep tech founders who aim to deliver a radically beneficial impact on human and planetary health. As of April 2022, our top 100 climate tech companies have an aggregate valuation of over $11 billion and have raised $3.85 billion, and our top 100 health startups are valued at $5.7 billion with $1 billion raised. Pitchbook ranks SOSV as a top investor in both categories.

SOSV helps build companies. Our startup development programs offer in-person and remote options with a 1:2 staff-to-founder ratio, including engineering, science, and startup experts working in advanced lab and fabrication facilities. This approach helps founders hit critical inflection points sooner, which speeds up fundraising and reduces dilution. SOSV helps founders go further, faster.

At SOSV, a pre-seed investment is the beginning, not the end. We start investing with up to $500,000 when a startup joins one of our programs. We continue funding successful companies through Seed, Series A, and beyond. Our general partners tap our network of thousands of investors to help founders find lead investors and syndicate partners. In 2021, SOSV made follow-on investments in 196 program alumni companies, and SOSV companies raised $2.2 billion.

SOSV has long recognized that great founders come from all backgrounds. Our 2,600 founders represent 84 nationalities and operate in 56 countries. 30% of our founders are from low- to middle-income countries, as defined by the World Bank. SOSV has a strong track record of investing in women entrepreneurs. SOSV has invested in 500 women founders, and 1 in 3 of our companies have at least one female founder.

At SOSV, we not only continue investing long after startups have completed our programs, we offer an open platform to support our program alumni. We continue to make investor introductions and provide ongoing access to experts on the SOSV teams. SOSV also maintains a vibrant, peer-to-peer founder community and programs private founder-focused events covering topics from legal to marketing.
Speedinvest is a leading early-stage venture capital firm with more than €1 billion AuM and 40 investors based in Berlin, London, Munich, Paris, and Vienna.

Our dedicated sector-focused teams are the first to fund Europe’s most innovative technology startups and our in-house operational experts are on-hand to offer founders ongoing support with growth, HR, market expansion, and more. Wefox, Bitpanda, TIER Mobility, GoStudent, Wayflyer, Open, CoachHub, Schüttflix, TourRadar, Adverity, and Twaice are among our portfolio of 250+ companies. Learn more at www.speedinvest.com.

Speedinvest
speedinvest.com

Contact:
innovateuk@speedinvest.com
Start Codon is a pre-seed/seed investment fund and venture builder that builds successful life science and healthcare/wellbeing start-ups across the UK. We focus on companies that have disruptive platform technologies with therapeutics, diagnostics, MedTech and/or digital health applications which address unmet needs. We invest in everything from university, corporate and institution ‘spin outs’, to entrepreneurs who have generated their own proprietary IP.

Our initial investments start from £250,000 and we can also provide additional/follow-on financing if certain criteria is met. Alongside our investment, as we are also a venture builder, we provide much needed and additional value-add over and above a traditional investor by helping founders to build and scale their venture from the ground up. This includes providing our companies with access to our ‘START’ venture building programme, through which we work hand-in-hand with our founders and their teams to help them craft their vision and to establish, build and scale their businesses. The START programme includes regular hands-on support from our experienced management team (which has a breadth of experience in product development, commercial strategy, legal and operations and HR/people management), mentorship from accomplished biotech and pharma executives and other industry leaders, access to a wide ranging and broad network of investors and industry partners and invites to regular events, seminars and educational sessions.

In addition, our portfolio companies may also get the opportunity to present their technology and company to a wide range of national and international investors and pharma and business partners at our annual "Innovation Showcase". By providing this support, we ensure that our portfolio companies hit their key milestones, scale at pace and thrive in a competitive market.

In order to apply for funding from us, entrepreneurs should complete the application form on our website at startcodon.co/contact. In addition to hearing from entrepreneurs spinning out of universities and other institutions, we encourage entrepreneurs with innovative life science/healthcare/wellbeing solutions developed outside of the more traditional life sciences/ healthcare/wellbeing arena (e.g. with self-generated IP or ideas) to apply for investment. Start Codon will also consider investments in early stage spin out opportunities from existing corporates.

Start Codon has a sizeable investment portfolio of exciting companies that is growing. We expect to invest in between 36 - 48 companies from our current fund before January 2025.
Sure Valley Ventures is a seed stage investor that helps exceptional founders of disruptive software companies to achieve rapid scale up. We have been investing in cutting edge AI since 2017.

What We Offer

We go the extra mile to support growth through our state-of-the-art Platform, which is tailored to each company's individual needs.

IPO support through our close partnership with Shard Capital & Fortified – IPO of Engage XR & Smarttech247 on the London Stock Exchange & more in progress

Large global network – over £130M third-party investment in our portfolio

Seed to Series A track record – 80% of our portfolio already raised Series A rounds, 70% within 24 months of investment (48% of companies fail to make the transition)

Deep technology expertise – As software founders turned investors, we have a deep understanding of the technical challenges faced by our companies

What We Look For

Sector

We specialise in investing, growing and scaling breakthrough companies with ambitious founders in the following sub-sectors of AI:

- Enterprise
- Immersive Technologies/ Creative Economy
- Security

Ticket Size

We typically invest between £750,000 - £1,500,000 at initial entry round and will look to follow up with further continued investment at later rounds.
Sustainable Ventures is one of the UK’s leading specialist climate tech investors, having made 36 investments to date. We provide capital at a pre-seed stage alongside 12-months of intensive support, expertise and access to our ecosystem, designed to rapidly accelerate product and commercial development. Interested SMEs should fill in the application on our website, including your pitch deck.

We only invest into startups that have climate change mitigation technology at their core. We look for UK-based companies raising money at pre-seed stage, with the following characteristics:

- Companies active within one of our core verticals: Agritech, Building Tech, Circular Economy, Energy and Mobility
- Must qualify for SEIS and/ or EIS tax relief
- Raising a pre-seed investment round of under £600k
- Have an MVP or prototype, with some form of defensible technology or business model in the form of IP or trade secrets
- A significant market opportunity, capable of delivering venture level returns
- Evidence of customer traction, for example pilots, letters of intent or grant funding
- At least 2 founders and a willingness to commit to the acceleration support that we provide

We are climate tech specialists having invested across a range of sectors over the past 5 years, including the following examples:

- Rovco – sub-sea submersible vehicle, 3D mapping and data analytics of the offshore industry. Rovco has just raised its Series B round and has expanded globally
- Airex – smart air brick technology to regulate airflow in domestic dwellings, reducing energy consumption. Airex is currently closing its Series A round
- Concrete4Change – novel capture technology to sequester carbon within cement

The companies we back can expect to receive the following support to help rapidly commercialise the innovations:

- Access to our shared workspaces in Central London and Manchester, alongside 70 other climate tech companies
- Tailored 1:1 support from our venture support team, focused on business development, product roadmap, operational design, team and board development, marketing and follow-on funding
- Connections with specialist service providers in IP protection, legal firms and accountancy
- Introductions into our Sustainable Ventures ecosystem, including corporates, innovation agencies, policy makers and investors. Invites to regular showcasing and networking events
Techstart Ventures is a pre-seed and seed stage venture capital investor for the best and most ambitious entrepreneurial founding teams in Scotland and Northern Ireland. We seek to be trusted peers who help founders realise their vision through experienced and timely support.

We are sector agnostic, aim to be the first institutional investor and typically write a first cheque of between £50k and £750k. We usually lead or co-lead our first rounds and have capacity to follow-on. Our portfolio companies have gone on to attract later stage investment from some of the world’s leading VC firms.

We are looking for exceptional founders who are pursuing uncapped opportunities and can articulate why they are the right team, and why now is the right time to be doing this.

Our direct portfolio support is supplemented by the Techstart Founders Community which is a peer-to-peer support platform open to all of our portfolio founders.
Tern Plc is a London-based venture capital investor, investing in early-stage IoT start-ups.

In addition to capital, Tern acts as a strategic and operational partner to our portfolio companies, to help them scale into the EU and US markets. All Tern partners have a wealth of global experience in scaling technology businesses, and we act as partners with our portfolio companies to support their growth prospects.
The Conduit EIS Impact fund invests in scalable impact ventures across the areas of Climate, Health, Inclusion and Education that benefit from EIS tax relief.

The fund only invests in companies that have been through the Conduit Connect’s rigorous impact screening framework, developed with Deloitte. The framework is aligned to the UN Sustainable Development Goals and ensures that all companies have social and/or climate impact at the core of their business models. The funds invest in seed and series A businesses with a strong preference for post revenue businesses.

The Conduit EIS Impact Fund team is a unique combination of experienced venture investors, operators, deal flow generators, capital connectors and impact experts.
The Yield Lab Europe is an Agtech impact venture capital fund, which invests into early stage European AgriFoodTech companies to make our global food and agriculture production system more sustainable and more efficient whilst improving profitability.

This includes technologies in crop production, animal health and welfare, precision agriculture, supply chain/logistics, food ingredients, supply chain, food processing and packaging. The Yield Lab Europe also runs an award-winning accelerator for earlier stage companies.
TSP Ventures is an early-stage investment firm investing in hard science and technology companies that address some of our most pressing environmental and climate challenges.

Our strapline ‘Enterprise, People, Earth’ (EPE) encapsulates our core belief, that the role of enterprise is to serve the long-term wellbeing of people and the Earth.

Our purpose is to do everything we can to help founders and businesses with an EPE mindset succeed and our mission is to shift the global allocation of capital towards businesses with an EPE mindset and purpose.

When assessing an investment, we focus on 4 key areas:

1. **Environmental impact:** Is the good, service or technology going to have a positive effect on people and the environment? Is this positive effect going to be significant and sustained?

2. **People:** Do the team have intelligence, experience, grit, determination enthusiasm, hunger and humility? Do they have an EPE mindset and are they hungry for success? These are not mutually exclusive.

3. **Technology and markets:** Here we are assessing saleability, scalability and defensibility of the product / business. In other words, is this a venture-style investment with the possibility of venture-style returns?

4. **Financial strategy:** Is enough money being raised at a reasonable enough valuation and utilised in a way that maximises the company’s chances of achieving its next milestone / valuation inflexion point?

Our focus is on hardware or hybrid (hardware plus software) solutions in the early stages of development (typically at TRLs 4-7). We have particular interests in: Energy / Decarbonising Heavy Industry; Water / Food; Carbon Capture, Utilisation & Storage (including nature-based e.g. soil health); Waste, Circularity, & Pollution.

We typically back companies from pre-seed through seed-extension to Series A.

We give a high degree of support to our investments to de-risk and turbo-charge them. We call this approach ‘Venture then Nurture’. We want our investments to know that they can be open and honest with us and in return, we will give our help, support and advice both frankly and wholeheartedly. This will always come from a place of care and trust.

We help our companies with strategy, future capital raisings, business negotiations, connections, hiring and coaching but this must be invited. We don’t want to interfere.
Twin Path Ventures is a pre-seed and seed fund on a mission to back AI-first startups with highly technical, intelligent and committed teams seeking to bring a proprietary advance in deep tech to an industry they know. We believe that doing AI well is still a deep tech / engineering challenge. By investing in deep-tech startups coming out of some of the world’s leading academic institutions we will be accessing some of the most cutting-edge technologies with the potential for high growth.

Our average ticket size is around £500k and we are looking for SEIS and EIS deals.

All three of our partners, John, Nick and Katie have worked or still do work partly as advisors and mentors in the startup ecosystem and have helped teams achieve product market fit. This should give you an indication of the level of empathy and founder alignment that you can expect from our team. We take board observer seats in every company we invest in, primarily as a way to support and advise early-stage teams.
Two Magnolias is an all-female GP led Impact Fund focused on backing exceptional founders who are solving the most pressing problems in the fields of Sustainability and Human Health.

Stage: Pre-Seed to Series A
Size: £100k-£500k ticket size
Pillars: Sustainability & Human Health

Two Magnolias is inspired by those who have the strength and courage to develop solutions needed to extend the life of our planet and the positive existence of humanity within it.

Mounting evidence shows that investment team diversity has a positive impact on cap tables. Diversity of thought brings a balance to decision making that is critical in the success of early-stage companies, and as a female led venture capital firm, that is what we bring.

Our Aim: To provide a multi-layered approach to Venture Capital Investing. As a team we commit to support and empower founders to succeed by sharing our vast experience across multiple business sectors. We will be present and accountable in our forward thinking approach every step of the way.

Our Focus: Investing in under-represented founders with particular focus on gender, ethnicity and the regions and devolved nations of the UK.

Two Magnolias value proposition: A vast network of professionals together with our 9-person Advisory Board provides access to subject matter expertise, personal networks, and large organisations such as the NHS, Universities, Government, and financial services.
At VisVires New Protein (VVNP), our primary focus is on investing in innovative companies that are developing game-changing solutions for the Food and Agricultural industries. We are committed to supporting Seed to Series B stage businesses that create scalable, mass-market solutions with global applicability. As a venture capital firm specializing solely in Agri–Food Tech, our in-depth understanding of the industry uniquely positions us to assist our portfolio companies.

With an Asian foundation and a strong emphasis on European markets, we provide a distinctive value proposition by bridging the gap between Europe and Asia. This strategic advantage enables us to support our portfolio companies if they plan to expand into the Asian market. VVNP is well-equipped to leverage its extensive network of industry experts, academics, and government contacts, to accelerate the business development of our portfolio companies. This value proposition is particularly relevant for companies operating in the food and agricultural industries, as Singapore is known as a global FoodTech hub, renowned for its unparalleled scientific innovation and supportive regulations.

Our deep-sector expertise allows us to help our portfolio companies establish a defensible edge, crafting business models that effectively create and capture value in the industry. Should you wish to contact us, our details are listed below. We would love to hear about your venture!
Zinc is an early stage mission-driven investor. We invest in founders to create innovative solutions and build ambitious businesses that tackle the most pressing and complex challenges facing the health of people and the planet. We select and invest in founders who can have outsized impact using cutting-edge science and technologies.

Our priority investment areas are full of underserved needs, affecting millions of people, for which ambitious and creative new solutions are needed:

**Health of People**
- Children’s health
- Chronic physical conditions in later life
- The adult brain
- Immune and digestive health
- Reproductive health
- Women’s health
- New models of health care
- Innovations in enabling technologies in health

**Health of Planet**
- Biomaterials and biochemicals
- Biodiversity, regeneration and nature-based solutions
- Heating and cooling
- Deep decarbonisation
- Critical minerals
- Pollutants
- Innovations in enabling technologies in environment

We believe that each of these areas presents exciting opportunities for commercial innovation and impact at scale.

Zinc brings together diverse cohorts of mission-aligned founders, many from untapped talent pools. We provide founders with access to capital, co-founders, expertise, network, coaching and our venture building platform.

Whether you’re a domain expert with deep insight into an important problem in health or the environment, or have developed innovative deep tech or deep science in the mission space, or are a business or technical leader ready to build and scale a purpose-driven venture, Zinc is the ideal place to build a mission-led business.